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Abstract
Glucose regulated protein 94 (Grp94) is the endoplasmic reticulum resident of the heat shock 
protein 90 kDa (Hsp90) family of molecular chaperones. Grp94 associates with many proteins 
involved in cell adhesion and signaling, including integrins, Toll-like receptors, immunoglobulins, 
and mutant myocilin. Grp94 has been implicated as a target for several therapeutic areas including 
glaucoma, cancer metastasis, and multiple myeloma. While 85% identical to other Hsp90 
isoforms, the N-terminal ATP-binding site of Grp94 possesses a unique hydrophobic pocket that 
was used to design isoform-selective inhibitors. Incorporation of a cis-amide bioisostere into the 
radamide scaffold led to development of the original Grp94-selective inhibitor, BnIm. Structure–
activity relationship studies have now been performed on the aryl side chain of BnIm, which 
resulted in improved analogues that exhibit better potency and selectivity for Grp94. These 
analogues also manifest superior antimigratory activity in a metastasis model as well as enhanced 
mutant myocilin degradation in a glaucoma model compared to BnIm.
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Molecular chaperones are responsible for the conformational maturation of nascent 
polypeptides into their bioactive conformations.1 One family of chaperones is the 90 kDa 
heat shock proteins (Hsp90), which has emerged as a promising therapeutic target for the 
treatment of many diseases.2–7 The Hsp90 family is responsible for the maturation of more 
than 200 client proteins, many of which belong to signaling pathways that are commonly 
hijacked in cancer. In fact, Hsp90 clients are directly associated with all ten hallmarks of 
cancer and thus represents a unique opportunity to simultaneously target multiple oncogenic 
pathways.8,9 Hsp90 exists as a homodimer within cells and consists of three domains: an N-
terminal domain, a middle domain, and a C-terminal dimerization domain. The N-terminal 
domain contains an ATP-binding pocket in which ATP hydrolysis provides the necessary 
energy for client protein maturation. The middle domain is responsible for client protein 
binding and interactions with cochaperones and partner proteins. The C-terminal domain 
contains a dimerization motif and is responsible for modulating client protein release.
The majority of Hsp90 research has focused on the development of N-terminal inhibitors, 
which compete with ATP within the binding site.10–12 N-terminal inhibitors have entered 
clinical studies for the treatment of various cancers.13–15 However, some concerns have been 
raised that must be addressed before new Hsp90 inhibitors are developed. A common factor 
among all clinical candidates is that they exhibit pan-Hsp90 inhibition, meaning they 
manifest similar affinities against all four Hsp90 isoforms: Hsp90α and Hsp90β are found in 
the cytosol, tumor necrosis factor receptor-associated protein 1 (Trap1) is localized to the 
mitochondria, and glucose regulated protein 94 (Grp94) resides in the endoplasmic 
reticulum (ER).
Many clients of the Hsp90-dependent protein folding process have been identified, however, 
clients with specific dependency on each isoform remain underinvestigated although some 
isoform-dependent substrates have been determined. For instance, maturation of the hERG 
channel and its trafficking to the cell surface was found to be solely dependent upon the 
Hsp90α isoform and suggests that inhibition of Hsp90α may contribute to some of the 
cardiotoxicity observed in clinical trials.16 It is also likely that other isoform-dependent 
client proteins contribute to other toxicities, which highlights the need to develop new 
strategies for Hsp90 inhibition. An alternative to pan-inhibition is the development of 
isoform-selective inhibitors. Such molecules would provide an opportunity to elucidate 
isoform-dependent client proteins associated with each isoform while simultaneously 
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reducing/derisking potential liabilities associated with pan-inhibition. Unfortunately, the 
development of isoform-selective inhibitors is challenging due to the fact that 85% identity 
is shared within the N-terminal ATP-binding site of all four Hsp90 isoforms. In fact, 
Hsp90α and Hsp90β are 95% identical within their N-terminal ATP-binding pocket, while 
Grp94 is least similar to only 85% identity.17–19
Grp94 is responsible for the maturation of proteins associated with cell-to-cell signaling and 
cell adhesion. Client proteins dependent upon Grp94 include many integrins (α-2, α-4, α-L, 
and β-4), Toll-like receptors (TLR1, TLR2, TLR4, and TLR9), insulin-like growth factor-I 
and -II, immunoglobulins, and mutant myocilin.5,20–22 Grp94 is essential only during 
embryonic development and therefore appears to represent a nontoxic drug target. However, 
overexpression of Grp94 is associated with tumor aggressiveness and poor clinical prognosis 
for cancer patients.23 In fact, Grp94 is responsible for the maturation and trafficking of 
proteins required for metastasis and cell migration and thus represents a nontoxic target for 
the development of antimetastatic agents. More recently, mutant myocilin has also been 
identified as a Grp94-dependent substrate and studies have shown that inhibition of Grp94 
leads to the disaggregation of mutant myocilin and consequently represents a novel target for 
the treatment of primary open-angle glaucoma (POAG).4,21,24 While Grp94 may represent 
an ideal target for cell migration and glaucoma, Grp94 has also been shown to be essential in 
multiple myeloma, which appears to possess increased ER stress. Inhibition of Grp94 has 
been shown to induce cell death in multiple myeloma, as disruption of interactions between 
Grp94 and LRP6 results in reduced cell-trafficking of LRP6 to the cell surface.3,5,25 LRP6 is 
a coreceptor of Frizzled in the Wnt pathway and reduction of these interactions leads to 
caspase 9 activation and apoptosis. Grp94 has also been shown to interact with Her2 and, 
consequently, disruption of these interactions leads to Her2 degradation via the lysosome 
and may represent an alternative mechanism to treat Her2 overexpressing breast 
cancers.26,27
Grp94 is least similar, in its N-terminal ATP-binding pocket, to other Hsp90 isoforms due to 
a five amino acid insertion (QEDGQ) into the primary sequence.22 This insertion results in 
the creation of a hydrophobic, secondary binding region within the N-terminal ATP-binding 
site of Grp94. As such, this unique pocket provides an opportunity to develop Grp94-
selective inhibitors.28,29 Prior studies via a high throughput screening method identified 
NECA (Figure 1) as a Grp94-selective inhibitor that bound to this secondary pocket.22,30 
Recently, a high throughput screen identified a series of Grp94-selective inhibitors based on 
the purine scaffold and subsequent optimization led to the development of 2.26 Co-
crystallization of 3 (Figure 1) with Grp94 showed this inhibitor to induce a conformational 
change within Grp94 that revealed an extended binding pocket distinct from the secondary 
pocket observed with NECA and RDA (4).26,27,30–32 Co-crystallization of the resorcinol 
containing pan-Hsp90 inhibitor, radamide (RDA, Figure 1) with canine Grp94 (cGrp94), 
revealed that the amide bond existed in both the cis- and trans-amide conformations.33 The 
cis-amide conformation projected the quinone moiety into the secondary binding pocket, 
while the trans-amide did not. On the basis of the RDA co-crystal structure, it was clear that 
a cis-amide conformation was required for selective Grp94 inhibition. The incorporation of a 
cis-amide bioisostere (e.g., imidazole) into the RDA scaffold predisposes the aryl ring into 
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the unique binding pocket found in Grp94 and ultimately led to the discovery of BnIm 
(Figure 1).28 BnIm demonstrates Grp94 selectivity in vitro as determined by inhibition of 
IGF-II secretion and the trafficking of Toll-like receptors at concentrations that did not result 
in cytosolic Hsp90-dependent client protein degradation. BnIm provided a lead compound 
for Grp94-selective inhibition, however, analysis of the unique binding pocket of Grp94 
revealed further interactions could be realized improving the selectivity and affinity of this 
scaffold for Grp94, reported herein.
GRP94-SELECTIVE INHIBITOR DESIGN, SYNTHESIS, AND BIOCHEMICAL 
SCREENING
The co-crystal structure of RDA with cGrp94 revealed the cis-amide to project the aryl side 
chain into the secondary binding pocket, which is surrounded by hydrophobic amino acids 
(Val82, Ile166, Ala167, Phe195, Val197, Phe199, Tyr200, and Trp223), suggesting that 
affinity may be increased through additional hydrophobic interactions (Figure 2a).33 In 
contrast, Hsp90β contains the backbone carbonyl of Asn92 and the ɛ-NH2 of Lys98, which 
blocks access to these hydrophobic residues and can be used as a paradigm to predict Grp94-
selective inhibition (Figure 2b). Docking of BnIm into the RDA co-crystal structure with 
Grp94 (PDB 2GFD) suggested that substitutions on the aryl side chain would provide 
additional interactions with the secondary pocket of Grp94, allowing for optimization of the 
aryl side chain for Grp94-selective inhibition. Nonpolar substitutions at the 4-position were 
proposed to extend further into the hydrophobic pocket and to produce increased affinity and 
selectivity. However, larger substitutions at this position would likely result in steric clash 
with Val82 and exhibit decreased affinity. Because of the close proximity of Tyr200 to the 3-
position of the aryl side chain, substitutions at this position appeared detrimental to Grp94 
affinity. Substitutions at the 2-position were likely to increase affinity through hydrophobic 
interactions with the secondary pocket. Furthermore, these substitutions have the potential to 
produce the conformational shift observed with the purine-based Grp94-selective inhibitor, 3 
(see Figure 4), and project into the extended binding pocket.26 On the basis of these 
observations, the aryl side chain of BnIm was investigated to probe the unique pocket 
present in Grp94 and to elucidate structure–activity relationships for optimal affinity and 
selectivity.
Because the cis-amide bioisostere, imidazole, could be prepared via a multicomponent 
cyclization reaction with an aromatic aldehyde, access to the desired analogues was achieved 
by varying the substitutions on the aryl amine component, which were either commercially 
available or readily accessible (Scheme 1). 4-Ethynylbenzylamine (6a) was synthesized 
from 4-iodobenzylamine following literature precedent.34 Aromatic nitriles were reduced 
using lithium aluminum hydride to produce the requisite amines (6b–e). The substituted 
benzoic acid was reduced to the corresponding benzyl alcohol, 8, using lithium aluminum 
hydride, and then converted to the corresponding azide, which was subsequently reduced to 
the desired amine, 6f, via Staudinger reduction. The basic amines were then cyclized with 
aldehyde 9 in the presence of ammonium bicarbonate and glyoxal, followed by desilylation 
with tetrabutylammonium fluoride to provide the desired analogues, 10–64 (Scheme 
2).28,35,36
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Once in hand, the analogues were screened via a competitive binding fluorescence 
polarization assay using Grp94 or Hsp90α and FITC-labeled geldanamycin (FITC-GDA). 
Geldanamcyin is a potent, natural product N-terminal pan-Hsp90 inhibitor that competes 
with Grp94 inhibitors for the N-terminal ATP-binding site.10 Analogues were originally 
screened at 25 μM to determine the percent of FITC-GDA (tracer) bound compared to 
vehicle control (0% tracer displaced, Table 1).
The 25 μM screen provided insight into the structural requirements for binding of the aryl 
side chain to the Grp94 secondary pocket. Substitutions at the 4-position typically 
maintained similar affinity as BnIm, but provided increased selectivity in several cases. As 
hypothesized, polar substitutions (17 and 21) manifested lower affinity due to the 
hydrophobic nature of the secondary binding pocket (Figure 2). Incorporation of a bicyclic 
system was not tolerated as the naphthyl (23 and 24) and quinoline (25) derivatives 
manifested decreased affinity for both Grp94 and Hsp90α. Substitutions at the 3-position 
were not beneficial, as all of the analogues resulted in decreased affinity for both isoforms 
compared to BnIm. Alternatively, substitutions at the 2-position typically increased Grp94 
affinity and improved selectivity versus Hsp90α.
Analogues that displaced ≥70% of the tracer when incubated with Grp94 at 25 μM were 
subsequently evaluated to determine their apparent Kd against Grp94 and Hsp90α. BnIm 
manifests an apparent Kd of 1.1 μM for Grp94 and 13.1 μM for Hsp90α. Substitutions at the 
4-position were designed to extend further into the hydrophobic pocket present in Grp94 and 
to increase selectivity over other isoforms. Modest increases in selectivity were observed 
with these compounds (11, 12, and 18), while increases in affinity were observed with 
analogues containing halogen substitutions. Incorporation of a larger methyl group (14) 
resulted in a substantial increase in selectivity for Grp94, as well as increased affinity. 
Extended alkyl chains (15 and 16) were too large for accommodation into the secondary 
pocket of Grp94 and resulted in decreased affinity.
As observed in the 25 μM screen, substitutions at the 3-position did not manifest improved 
affinity nor selectivity for Grp94 compared to BnIm (26–32). Alternatively, substitutions at 
the 2-position provided additional insights into the modes of binding for these analogues. 
Small substitutions at the 2-position were tolerated, however, such substitutions did not 
increase selectivity or affinity. Larger substitutions produced increased selectivity for Grp94 
versus other Hsp90 isoforms, as 38, 39, and 40 manifested >40-fold selectivity for Grp94 
over Hsp90α, which is likely due to induction of a conformational shift in the tertiary 
structure of Grp94. Patel and colleagues previously reported the co-crystallization of 3 with 
Grp94 (PDB 3O2F), in which a conformational shift was observed that resulted in an 
extended binding region within the Grp94 ATP-binding site.26,31 This pocket is distinct from 
the secondary pocket observed with NECA and RDA (Figure 3), as this region opens due to 
the migration of Phe199, which allows additional access to the binding pocket as observed 
with 3. Substitutions at the 2-position may also induce a similar conformational change in 
Grp94, which allows access to this region and increases selectivity for Grp94. In the case of 
40 (Grp94 apparent Kd = 0.2 μM; 41-fold selective), the increased selectivity was 
accompanied by a ~6-fold increase in affinity for Grp94 compared to BnIm. Extension or 
branching of the alkyl ether (41 and 42) improved affinity for Grp94, although a loss in 
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selectivity was observed. Larger alkyl ethers were not accommodated within the secondary 
binding pocket of Grp94 and likely push the benzyl side chain toward the solvent exposed 
region to form hydrogen bonds with polar amino acids. Such polar residues are present in 
both Grp94 and Hsp90 and provides an explanation for the loss of selectivity and an increase 
in affinity. 44 was synthesized in an attempt to combine beneficial substitutions observed 
with the 2- and 4-positions, however, affinity was compromised as compared to the parent 
compounds (14 and 38), suggesting the effects of these substitutions are not additive (Table 
1).
Because of the high density of aromatic amino acids within the unique secondary binding 
pocket of Grp94, the incorporation of heterocycles was proposed to improve both π–π 
interactions and affinity for Grp94.33 The requisite heterocyclic amines (6g–l) were 
synthesized from the corresponding aldehydes through conversion to the oximes (66a–e) 
followed by reduction via lithium aluminum hydride (Scheme 3). Chlorination of 
thiophen-2-ylmethanamine via sulfuryl chloride provided 6m (Scheme 4). Radical 
bromination of 5-methylisoxazole followed by conversion to the azide and subsequent 
reduction resulted in 6n. The aromatic carboxylic acid 68 was reduced to the corresponding 
alcohol using lithium aluminum hydride followed by conversion to the azide and then 
Staudinger reduction to yield 6o. Deprotonation of 3-chlorothiophene with n-butyllithium 
followed by the addition of CO2(g) provided a mixture of carboxylate regioisomers which 
were separable via flash chromatography after reduction to the corresponding alcohols (69b 
and 69c) with lithium aluminum hydride. These isomers were then converted to the 
corresponding azides, followed by Staudinger reduction to provide the requisite basic 
amines, 6p and 6q (Scheme 4). The desired analogues were obtained through the 
multicomponent reaction detailed in Scheme 2 to produce analogues 45–64.
As can be seen in Table 2, the incorporation of an electron poor (compared to benzene) 
pyridine ring (61–64) resulted in decreased selectivity and affinity for Grp94. In contrast, the 
incorporation of electron rich five-membered heterocycles proved beneficial for Grp94 
affinity. Converting the phenyl ring of BnIm to the bioisosteric replacement, thiophene (50), 
resulted in a significant increase in Grp94 affinity compared to BnIm. The furan and 
thiophene (46 and 50, respectively) analogues exhibited both increased affinity and 
selectivity and consequently, substitutions about these rings were explored. The energy 
minimized structures of BnIm and 46 were overlaid and revealed the 5-position of the 
heterocycle to align similar to the 4-position of the BnIm benzyl side chain (Figure 4). 
Therefore, substitutions at the 5-position of both the furan and thiophene rings were sought 
to achieve increased selectivity and affinity.
53 was shown to manifest improved selectivity for Grp94 compared to the 3- and 4-chloro 
substituted thiophene analogues (55 and 55), supporting the hypothesis that 5-substituents 
bind similar to the 4-substituted phenyl ring. Incorporation of a 5-chloro substitution on the 
smaller furan ring (48) resulted in increased affinity for Grp94 while maintaining selectivity. 
However, incorporation of an ethyl substitution at the 3-position of the thiophene to mimic 
the 2-position of the benzene ring resulted in both reduced affinity and selectivity.
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CO-CRYSTALLIZATION OF GRP94 WITH A GRP94-SELECTIVE INHIBITOR
The co-crystal structure of the N-terminal domain of Grp94 lacking the acidic linker (NΔ41, 
see Experimental Section) in complex with 48 (referred to as VC3 in the PBD file) was 
solved to 2.6 Å resolution to support the proposed docking interactions (Figure 5a, 
Supporting Information, Table 1). The structure reveals 48 in the ATP-binding site is 
stabilized by hydrogen bonding interactions with Asp149 (Figure 5b,c), similar to other 
resorcinol-based pan-Hsp90 inhibitors. There are few other direct interactions between 48 
and the NΔ41 ATP-binding site, which are mediated through conserved water molecules 
(Figure 5c). In contrast to RDA, 48 is bound to Grp94 in a single orientation, illustrating the 
effectiveness of the cis-amide bioisostere in reducing binding heterogeneity.
The electron density for 48 was largely continuous for the length of the molecule, with the 
notable exception of the chlorinated furan moiety (Figure 5d), which apparently samples 
multiple conformations within the ATP-binding site. It is possible that the chlorinated furan 
dwells in the extended hydrophobic region to increase selectivity (as predicted through 
modeling studies); however, the final binding mode modeled, based on optimal fit to 2Fo − 
Fc (Figure 5d) and Fo − Fc difference density (not shown), is one in which the chloride 
substituent is nestled in an ordered loop (residues 165–170) at the entry to the ATP-binding 
site (arrow, Figure 5a,b). Notably, this loop is disordered in the structure complexed with 
RDA. The furan moiety also appears to be involved in a cation–π interaction with Lys168 to 
stabilize this loop. In general, phenyl rings form stronger cation–π interactions due to a 
larger quadrapole moment compared to furan rings. However, modeling studies suggest that 
the phenyl ring of BnIm cannot orient in a manner that allows this interaction (data not 
shown) and therefore accounts for the increased affinity manifested by the smaller 
heterocycles (45–60). Taken together, 48, and by analogy other analogues described within 
this series, bind to the ATP-binding site of Grp94 in a mode that manifests increased 
selectivity over the other Hsp90 isoforms.
GRP94-SELECTIVE INHIBITION IN CANCER
Grp94 is responsible for the maturation and trafficking of several proteins associated with 
cell signaling and adhesion. One such client of Grp94 are the integrins, which are essential 
for cell adhesion and migration through promoting interactions between the intracellular 
actin cytoskeleton and the extracellular matrix.37–39 Integrins are dependent upon Grp94 for 
not only their maturation but also their transport to the cell surface. Therefore, inhibition of 
Grp94 leads to decreased trafficking of integrins to the cell surface and results in decreased 
integrin expression at the cell surface. As a result, decreased cell migration is observed and 
provides a new opportunity for the development of antimetastatic agents.29,40,41 For 
example, selective inhibition of Grp94 results in decreased migration of MDA-MB-231 
cells, an aggressive form of metastatic breast cancer. In a wound-healing scratch assay, 
Grp94-selective inhibitors, 40 and 48, produced decreased wound closing at 24 h compared 
to BnIm and vehicle control (70% and 73% closed at 500 nM, respectively, Figure 6). In 
fact, these analogues manifested superior antimigratory activity compared to BnIm at 10-
fold lower concentrations. Furthermore, these analogues were evaluated for antiproliferative 
activity against the same cell line and were found to manifest no antiproliferative activity up 
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to 100 μM (78% and 107% viable at 100 μM, respectively, Figure 6), confirming that the 
antimigratory activity is not linked to cell viability. These data are in agreement with the 
nonessential nature of Grp94 and provides a large therapeutic window for the development 
of Grp94-selective inhibitors as a new class of antimetastatic agents.
Recently, integrin α2 was determined to be dependent upon Grp94 for its maturation and 
trafficking to the cell surface through proteomic and Western blot analyses of Grp94 
knockdown cells.42 Similarly, selective inhibition of Grp94 resulted in the degradation of 
integrin α2 (Figure 7A,B). Integrin α2 forms a heterodimer with integrin β1 on the cell 
surface,38 which is responsible for binding to collagen in the extracellular matrix to promote 
metastasis and invasion. 40 and 48 both induced the degradation of integrin α2, providing 
evidence that the decrease in cell migration results from Grp94-selective inhibition. 
Furthermore, 40 and 48 do not result in the degradation of Akt (Figure 7C), a well-known 
client protein that is dependent upon the cytosolic isoforms of Hsp90. It should be noted that 
a slight induction of the pro-survival heat shock response was observed with 40 and 48 
(Figure 7D). However, this occurred at concentrations 10–50-fold higher than antimigratory 
activity was demonstrated.
PRIMARY OPEN ANGLE GLAUCOMA AND GRP94-SELECTIVE INHIBITION
Although POAG is characterized clinically by irreversible optic nerve damage and retinal 
ganglion cell death that leads to vision loss, the risk factor of elevated intraocular pressure 
typically results from decreased outflow of the aqueous humor through Schlemm’s canal of 
the trabecular meshwork (TM) extracellular matrix in the anterior segment of the eye. A 
contributor to TM dysfunction is TM cell death,24,43 which can be brought about by the 
aggregation of mutant myocilin.44 Nonsynonymous mutations in myocilin, localized to its 
olfactomedin domain, result in non-native tertiary structures, which promote facile 
aggregation and leads to TM cell death.43,45 Recently, it was demonstrated that Grp94 
associates with amyloid-like aggregates of mutant myocilin but cannot triage these 
aggregates for degradation through the ER-associated degradation (ERAD) pathway.4 Our 
prior studies showed that inhibition of Grp94 allows mutant myocilin degradation through 
autophagy, which decreases intracellular levels of myocilin and, ultimately, reduces 
toxicity.21 Therefore, these newly designed Gpr94-selective inhibitors were evaluated for 
their ability to promote mutant myocilin clearance in an inducible HEK model. Treatment 
with 48 resulted in a substantial decrease of mutant myocilin levels at 1 μM (Figure 8A,C), 
however, treatment with 40 only resulted in a slight decrease in myocilin levels. The 
difference in activity between 40 and 48 is not readily clear and is currently being 
investigated in our laboratory. As expected, 40 and 48 did not induce the degradation of the 
cytosolic Hsp90 isoform-dependent client, Akt (Figure 8B,D), nor was there any measurable 
induction of the pro-survival heat shock response, as monitored by Hsp70 induction (Figure 
8E). This is in contrast to Western blot analysis of the MDA-MB-231 cell line above (Figure 
7) and is due to the Hsp90 isoforms in cancer cells having a higher affinity for inhibitors 
(and ATP) compared to the Hsp90 isoforms in nontransformed cells.46
Crowley et al. Page 8














Structure–activity relationship studies were performed on the aryl side chain of BnIm, which 
interacts with the unique secondary pocket of Grp94 (Figure 9). Substitutions at the 2-and 4-
positions were tolerated within this binding region. Incorporation of an ethoxy group at the 
2-position manifested a significant increase in affinity, as well as selectivity. 40 manifests 
nearly a 10-fold increase in affinity for Grp94 compared to BnIm and 40-fold selectivity for 
Grp94 over the cytosolic Hsp90 isoforms. Replacing the phenyl ring of the side chain with 
five-membered heterocycles also resulted in increased affinity for Grp94 as observed with 
48. A crystal structure of the N-terminal domain of Grp94 was solved revealing a cation–π 
interaction between the furan ring and Lys168, which accounts for the increased affinity 
observed with the five-membered heterocycles. Grp94-selective inhibition reduced cell 
migration of aggressive breast cancer cells without manifesting toxicity and thus provided a 
large therapeutic index. Additionally, Grp94 inhibition resulted in the degradation of 
myocilin aggregates and provides a nontoxic approach to the treatment of POAG. These data 
presented herein provide a strong foundation for the further development of rationally 
designed Grp94-selective inhibitors for the treatment of metastasis and POAG.
EXPERIMENTAL SECTION
Chemistry General
1H NMR were recorded at 400 (Bruker AVIIIHD 400 MHz NMR with a broadband X-
channel detect gradient probe) or 500 MHz (Avance AVIII 500 MHz spectrometer with a 
dual carbon/proton cryoprobe), and 13C were recorded at 125 MHz (Bruker AVIII 
spectrometer equipped with a cryogenically cooled carbon observe probe); chemical shifts 
are reported in δ (ppm) relative to the internal standard (CDCl3, 7.26 ppm or MeOD, 3.31 
ppm). HRMS spectra were recorded with a LCT Premier (Waters Cor., Milford, MA). The 
purity of compounds was determined by HPLC (Agilent 1100 series quaternary pump; 60% 
MeCN/40% water; Agilent C-18 column, 4.6 mm × 150 mm, 5 μM) with UV detection. All 
biologically tested compounds were determined to be >95% pure. TLC analysis was 
performed on glass backed silica gel plates and visualized by UV light. All solvents were 
reagent grade and used without further purification.
General Procedure for Multicomponent Cyclization Reaction
Basic amines (e.g., 6a–6q, 0.26 mmol) were added to a stirred solution of 9 (125 mg, 0.26 
mmol) in wet MeOH (2 mL) and stirring continued for 30 min at rt before the addition of 
NH4HCO3 (0.26 mmol) and glyoxal (0.26 mmol). After stirring for 12 h, 
tetrabutylammonium fluoride (0.52 mL of 1 M solution in THF, 0.52 mmol) was added and 
then stirred for 30 min before the reaction was quenched with saturated aqueous NH4Cl (10 
mL) and extracted with EtOAc (3 × 10 mL). The organic layers were combined, dried 
(Na2SO4), filtered, and concentrated. The residue was purified via flash chromatography 
(SiO2, 1:49 MeOH:DCM) to afford the desired product as amorphous solids.
Methyl 2-(2-(1-Benzyl-1H-imidazol-2-yl)ethyl)-3-chloro-4,6-dihydroxybenzoate 
(5)—Yield 54 mg (54%), white amorphous solid. 1H NMR (500 MHz, CDCl3, MeOD) δ 
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7.28−7.23 (m, 3H), 7.01−6.97 (m, 2H), 6.95 (d, J = 1.5 Hz, 1H), 6.81 (d, J = 1.5 Hz, 1H), 
6.40 (s, 1H), 5.02 (s, 2H), 3.79 (s, 3H), 3.48−3.41 (m, 2H), 2.89−2.83 (m, 2H). 13C NMR 
(126 MHz, CDCl3, MeOD) δ 170.81, 162.06, 158.06, 147.65, 141.73, 136.17, 128.93, 
127.99, 126.91, 126.53, 120.10, 114.76, 105.88, 102.46, 52.45, 49.38, 30.77, 26.08. HRMS 
(ESI) m/z [M –H]− C20H19ClN2O4 385.0955, found 385.0953. tR = 5.062 min, 99.0%.
(4-Ethynylphenyl)methanamine (6a)—6a was synthesized from 4-iodobenzylamine 
hydrochloride following procedures detailed in ref 34. Yield 93 mg (78%) as a dark-yellow 
oil. 1H NMR (500 MHz, MeOD) δ 7.54 (d, J = 8.2 Hz, 2H), 7.44 (d, J = 8.3 Hz, 2H), 4.13 
(s, 2H), 3.60 (s, 1H). 13C NMR (126 MHz, MeOD) δ 133.56, 132.27 (2C), 128.71 (2C), 
123.34, 82.10, 78.58, 42.51. HRMS (ESI) m/z [M + H]+ for C9H10N 132.0813, found 
132.0809.
General Procedure for Reduction of Aromatic Nitriles
Benzonitriles (e.g., 7a–7c, 0.7 M in THF, 1 equiv) were added dropwise to a stirred solution 
of LiAlH4 (0.5 M in dry THF, 5 equiv) at 0 °C. The reaction mixture warmed to rt and 
stirred for 12 h. H2O (1 mL/g of LiAlH4) was added dropwise to quench the excess hydride, 
followed by 4 M NaOH (1 mL/g of LiAlH4) and EtOAc (3 mL/g of LiAlH4). The resulting 
suspension was filtered through a pad of Celite and the Celite washed with warm EtOAc (30 
mL) and the eluent concentrated. The residue was purified via flash chromatography (SiO2, 
1:49, MeOH:DCM to 1:20, MeOH:DCM) to afford the desired product as oils.
(2-Ethylphenyl)methanamine (6b)—Yield 653 mg (79%) as a colorless oil. 1H NMR 
(400 MHz, MeOD) δ 6.77−6.69 (m, 1H), 6.63−6.56 (m, 2H), 6.58−6.48 (m, 1H), 4.51 (s, 
2H), 2.07 (q, J = 7.6 Hz, 2H), 0.60 (t, J = 7.6 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 
143.24, 129.80, 129.39, 129.10, 127.47, 126.97, 42.31, 26.37, 15.96. HRSM (ESI) m/z [M + 
NH4]+ for C9H17N2 153.1392, found 153.1395.
(2-Ethoxyphenyl)methanamine (6c)—Yield 215 mg (59%) as a colorless oil. 1H NMR 
(400 MHz, CDCl3) δ 7.25−7.16 (m, 2H), 6.90 (t, J = 7.4 Hz, 1H), 6.85 (d, J = 8.5 Hz, 1H), 
4.07 (q, J = 7.6, 7.1 Hz, 2H), 3.82 (s, 2H), 1.73 (br s, 2H), 1.44 (t, J = 7.0 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 156.82, 131.81, 128.52, 128.05, 120.37, 111.07, 63.33, 42.88, 14.98. 
HRMS (ESI) m/z [M + H]+ for C9H14NO 152.1075, found 152.1077.
(2-Isopropoxyphenyl)methanamine (6d)—Yield 243 mg (59%) as a colorless oil. 1H 
NMR (400 MHz, CDCl3) δ 7.19 (t, J = 6.6 Hz, 2H), 6.92−6.83 (m, 2H), 4.59 (hept, J = 6.0 
Hz, 1H), 3.79 (s, 2H), 1.74 (br s, 2H), 1.36 (d, J = 6.1 Hz, 6H). 13C NMR (126 MHz, 
CDCl3) δ 155.74, 132.68, 128.74, 127.95, 120.24, 112.53, 69.73, 43.07, 22.23 (2C). MS 
(EI) m/z [M]+ for C10H15NO 165.1, found 165.2.
(2-Propoxyphenyl)methanamine (6e)—Yield 265 mg (67%) as a colorless oil. 1H 
NMR (400 MHz, CDCl3) δ 7.24−7.16 (m, 2H), 6.90 (t, J = 7.4 Hz, 1H), 6.85 (d, J = 8.5 Hz, 
1H), 3.96 (t, J = 6.4 Hz, 2H), 3.83 (s, 2H), 1.90−1.78 (m, 4H), 1.06 (t, J = 7.4 Hz, 3H). 13C 
NMR (126 MHz, CDCl3) δ 156.94, 131.72, 128.50, 128.08, 120.33, 111.02, 69.26, 42.85, 
22.70, 10.78. MS (EI) m/z [M]+ for C10H15NO 165.1, found: 165.2.
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General Procedure for Staudinger Reduction
PPh3 (1.1 equiv) was added to a stirred solution of the benzyl azide (1 equiv) in THF:H2O 
(0.1 M, 10:1) and stirred at rt for 12 h. The reaction mixture was concentrated, and the 
residue was purified via flash chromatography (SiO2, 1:49, MeOH:DCM to 1:20, 
MeOH:DCM) to afford the desired product as oils.
(2-Methoxy-4-methylphenyl)methanamine (6f)—Yield 99 mg (73%) as a colorless 
oil. 1H NMR (500 MHz, CDCl3) δ 7.08 (d, J = 7.4 Hz, 1H), 6.72 (d, J = 7.4 Hz, 1H), 6.69 (s, 
1H), 3.83 (s, 3H), 3.77 (s, 2H), 2.34 (s, 3H), 1.87 (br s, 2H). 13C NMR (126 MHz, CDCl3) δ 
157.32, 138.16, 128.47, 120.96, 111.24, 74.80, 55.12, 42.39, 21.55. HRMS (ESI) m/z [M + 
H]+ for C9H14NO 152.1075, found 152.1076.
General Procedure for Oxime Reduction
Aryl oximes (e.g., 66a–66e, 0.7 M in THF, 1 equiv) were added dropwise to a stirred 
solution of LiAlH4 (0.5 M in dry THF, 5 equiv) at 0 °C. The reaction mixture warmed to rt 
and stirred for 12 h. H2O (1 mL/g of LiAlH4) was added dropwise to quench the excess 
hydride, followed by 4 M NaOH (1 mL/g of LiAlH4) and EtOAc (3 mL/g of LiAlH4). The 
resulting suspension was then filtered through a pad of Celite and the Celite washed with 
warm EtOAc (30 mL), and the eluent was concentrated. The residue was purified via flash 
chromatography (SiO2, 1:49, MeOH:DCM to 1:20, MeOH:DCM) to afford the desired 
products as oils.
(5-Chlorofuran-2-yl)methanamine (6g)—Yield 93 mg (47%), yellow oil. 1H NMR 
(500 MHz, CDCl3) δ 6.12 (d, J = 3.2 Hz, 1H), 6.06 (d, J = 3.2 Hz, 1H), 3.76 (d, J = 0.8 Hz, 
2H), 1.58 (br s, 2H). 13C NMR (126 MHz, CDCl3) δ 156.24, 156.23, 135.05, 107.49, 
106.62, 39.35. HRMS (ESI) m/z [M + H]+ for C5H7ClNO 132.0216, found 132.0221.
Thiazol-2-ylmethanamine (6h)—Yield 42 mg (9%) as a red oil. 1H NMR (400 MHz, 
CDCl3) δ 7.72 (d, J = 3.1 Hz, 1H), 7.26 (d, J = 3.2 Hz, 1H), 4.20 (s, 2H), 1.80 (br, s, 
2H). 13C NMR (126 MHz, CDCl3) δ 174.02, 142.60, 118.56, 44.04. HRMS (ESI) m/z [M + 
H]+ for C4H7N2S 115.0330, found 115.0331.
(5-Methylthiophen-2-yl)methanamine (6i)—Yield 72 mg (16%) as a yellow oil. 1H 
NMR (500 MHz, CDCl3) δ 6.70 (d, J = 3.4 Hz, 1H), 6.57 (dd, J = 3.3, 1.3 Hz, 1H), 3.96 (s, 
2H), 2.72 (br s, 2H), 2.44 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 143.88, 138.89, 124.79, 
124.03, 41.20, 15.40. HRMS (ESI) m/z [M + H]+ for C6H10NS 128.0534, found 128.0532.
(3-Vinylthiophen-2-yl)methanamine (6j)—Yield 152 mg (42%) as a yellow oil. 1H 
NMR (400 MHz, CDCl3) δ 7.20−7.07 (m, 1H), 6.73 (dd, J = 17.5, 11.0 Hz, 1H), 5.54 (dd, J 
= 17.4, 1.3 Hz, 1H), 5.24 (dd, J = 11.0, 1.3 Hz, 1H), 4.07 (s, 1H), 2.03 (s, 1H). 13C NMR 
(126 MHz, CDCl3) δ 142.46, 135.23, 128.76, 125.43, 123.24, 114.19, 38.92. HRMS (ESI) 
m/z [M + H]+ for C7H10NS 140.0534, found 140.0531.
(3-Vinylfuran-2-yl)methanamine (6k)—Yield 57 mg (24%) as a yellow oil. 1H NMR 
(400 MHz, CDCl3) δ 7.29 (dd, J = 2.0, 0.7 Hz, 1H), 6.57 (dd, J = 17.3, 10.7 Hz, 1H), 6.50 
Crowley et al. Page 11













(d, J = 2.0 Hz, 1H), 5.42 (dd, J = 17.4, 1.4 Hz, 1H), 5.14 (dd, J = 10.8, 1.4 Hz, 1H), 3.85 (s, 
2H), 1.67 (br s, 2H). 13C NMR (126 MHz, CDCl3) δ 152.77, 141.68, 126.24, 119.34, 
113.23, 107.72, 37.05. HRMS (ESI) [M + H]+ for C7H10NO 124.0762, found 124.0768.
(3-Ethylthiophen-2-yl)methanamine (6l)—Pd/C 10% (5 mol %) was added to a stirred 
solution of (3-vinylthiophen-2-yl)methanamine (6k, 50 mg, 0.36 mmol) in MeOH (5 mL) 
and stirred at rt under a hydrogen atmosphere for 12 h. The reaction mixture was filtered 
through a pad of Celite, and the eluent was concentrated to produce the title compound 
which was used without further purification. Yield 45 mg (89%) as a yellow oil. 1H NMR 
(400 MHz, CDCl3) δ 7.16 (d, J = 5.1 Hz, 1H), 6.87 (d, J = 5.2 Hz, 1H), 4.56 (s, 2H), 4.05 (s, 
2H), 2.61 (q, J = 7.6 Hz, 2H), 1.20 (t, J = 7.6 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
141.48, 134.90, 128.62, 123.84, 37.77, 21.46, 15.29. HRMS (ESI) m/z [M + H]+ for 
C7H12NS 147.0690, found 147.0692.
(5-Chlorothiophen-2-yl)methanamine (6m)—A solution of thiophene-2-
ylmethanamine (1 mL, 9.7 mmol, 1 equiv) in AcOH:Et2O (9:1, 0.5 M) was cooled to 5 °C 
followed by the dropwise addition of SO2Cl2 (1.18 mL, 14.6 mmol, 1.5 equiv), maintaining 
the reaction temperature under 20 °C. The reaction was stirred at rt for 1 h, at which time 
Et2O (20 mL) was added and stirred for an additional 30 min. The precipitate (hydrochloride 
salt of desired product) was filtered and the solid washed with Et2O. The isolated solid was 
dissolved in DCM (25 mL) and washed with sat’d NaHCO3 (2 × 30 mL). The organic layer 
was separated, dried (Na2SO4), and concentrated. The residue was purified via flash 
chromatography (SiO2, 1:49 MeOH:DCM to 1:20 MeOH:DCM) to provide the title 
compound. Yield 658 mg (37%) as a yellow oil. 1H NMR (400 MHz, MeOD) δ 5.51 (d, J = 
3.0 Hz, 1H), 5.40 (d, J = 3.8 Hz, 1H), 2.69 (s, 2H), 1.73 (br s, 2H). 13C NMR (126 MHz, 
MeOD) δ 134.70, 132.71, 130.62, 127.93, 38.70. HRMS (ESI) m/z [M + H]+ for C5H6ClNS 
148.9990, found 148.9988.
Isoxazol-5-ylmethanamine (6n)—Yield 159 mg (77%) as a colorless oil. 1H NMR (400 
MHz, CDCl3) δ 8.17 (s, 1H), 6.13 (s, 1H), 4.00 (s, 2H), 1.53 (br, s, 2H). 13C NMR (126 
MHz, CDCl3) δ 172.47, 150.28, 100.04, 37.62. MS (EI) m/z [M]+ for C4H6N2O 98.0, found 
98.1.
(3,5-Dimethylfuran-2-yl)methanamine (6o)—Yield 98 mg (65%) as a yellow oil. 1H 
NMR (400 MHz, MeOD) δ 5.78 (s, 1H), 3.70 (s, 2H), 2.17 (s, 3H), 1.92 (s, 3H). 13C NMR 
(126 MHz, MeOD) δ 152.01, 147.87, 118.48, 110.06, 36.39, 13.41, 9.78. HRMS (ESI) m/z 
[M + H]+ for C7H12NO 126.0919, found 126.0924.
(3-Chlorothiophen-2-yl)methanamine (6p)—Yield 113 mg (59%) as a yellow oil. 1H 
NMR (400 MHz, CDCl3) δ 7.15 (dd, J = 5.2, 1.2 Hz, 1H), 6.86 (dd, J = 5.3, 1.1 Hz, 1H), 
3.98 (s, 2H), 1.79 (br s, 2H). 13C NMR (126 MHz, CDCl3) δ 148.24, 124.45, 123.90, 
118.33, 41.51. HRMS (ESI) m/z [M + H]+ for C5H7ClNS 147.9988, found 147.9990.
(4-Chlorothiophen-2-yl)methanamine (6q)—Yield 79 mg (67%) as a yellow oil. 1H 
NMR (400 MHz, CDCl3) δ 6.96 (s, 1H), 6.78 (s, 1H), 3.99 (s, 2H), 1.71 (br s, 2H). 13C 
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NMR (126 MHz, CDCl3) δ 148.24, 124.45, 123.90, 118.33, 41.51. HRMS (ESI) m/z [M + 
H]+ for C5H7ClNS 147.9988, found 147.9995.
General Procedure for Alkylation of 2-Hydroxybenzonitrile
Alkyl iodides (3.7 mmol, 1.1 equiv) and K2CO3 (930 mg, 6.7 mmol, 2 equiv) were added to 
a stirred solution of 2-hydroxybenzonitrile (400 mg, 3.4 mmol) in DMF (20 mL) at rt and 
stirred for 4 h. The reaction was quenched with the addition of H2O (20 mL) and EtOAc (40 
mL). The organic layer was washed with water (5 × 40 mL), dried (Na2SO4), filtered, and 
concentrated. The residue was purified by column chromatography (SiO2, 4:1 Hex:EtOAc) 
to afford the desired alkyl ethers as colorless oils.
2-Ethoxybenzonitrile (7a)—Yield 360 mg (71%) as a colorless oil. 1H NMR (400 MHz, 
CDCl3) δ 7.63−7.45 (m, 2H), 7.04−6.89 (m, 2H), 4.15 (q, J = 7.1 Hz, 2H), 1.48 (t, J = 7.0 
Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 161.02, 134.65, 134.17, 120.91, 116.99, 112.49, 
102.36, 64.99, 14.91. MS (EI) m/z [M]+ for C9H9NO 147.1, found 147.1; [M + H]+ for 
C9H10NO 148.1, found 148.1.
2-Isopropoxybenzonitrile (7b)—Yield 405 mg (71%) as a colorless oil. 1H NMR (400 
MHz, CDCl3) δ 7.57 (dt, J = 7.7, 1.5 Hz, 1H), 7.52 (td, J = 7.9, 7.3, 1.5 Hz, 1H), 6.99 (dd, J 
= 8.2, 5.2 Hz, 2H), 4.68 (hept, J = 6.1 Hz, 1H), 1.43 (d, J = 6.1 Hz, 6H). 13C NMR (126 
MHz, CDCl3) δ 159.92, 134.11, 133.94, 120.45, 116.77, 113.64, 102.99, 71.78, 21.86 (2C). 
MS (EI) m/z [M]+ for C10H11NO 161.1, found 161.1; [M + H]+ for C10H12NO 162.1, found 
162.1.
2-Propoxybenzonitrile (7c)—Yield 385 mg (71%) as a colorless oil. 1H NMR (400 
MHz, CDCl3) δ 7.55 (d, J = 7.8 Hz, 1H), 7.50 (td, J = 8.1, 7.4, 1.5 Hz, 1H), 7.00−6.93 (m, 
2H), 4.03 (t, J = 6.5 Hz, 2H), 1.88 (h, J = 7.0 Hz, 2H), 1.08 (t, J = 7.4 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 160.83, 134.27, 133.76, 120.52, 116.56, 112.19, 102.00, 70.45, 22.33, 
10.46. MS (EI) m/z [M]+ for C10H11NO 161.1, found 161.1; [M + H]+ for C10H12NO 162.1, 
found 162.1.
General Procedure for the Reduction of Carboxylic Acids
The aromatic carboxylic acids (e.g., 68, 0.7 M in THF, 1 equiv) were added dropwise to a 
stirred solution of LiAlH4 (0.5 M in THF, 5 equiv) at 0 °C. The reaction warmed to rt and 
stirred for 12 h. H2O (1 mL/g of LiAlH4) was added, to quench the excess hydride, then 4 M 
NaOH (1 mL/g of LiAlH4) and EtOAc (3 mL/g of LiAlH4). The resulting suspension was 
filtered through a pad of Celite then the Celite was washed with warm EtOAc and the eluent 
concentrated. The residue was purified via flash chromatography (SiO2, 3:10 
EtOAc:hexanes to 3:5 EtOAc:hexanes) to provide the desired alcohol as colorless oils:
(2-Methoxy-4-methylphenyl)methanol (8)—Yield 187 mg (50%), colorless oil. 1H 
NMR (400 MHz, CDCl3) δ 7.14 (d, J = 7.5 Hz, 1H), 6.78 (dd, J = 7.5, 0.8 Hz, 1H), 6.75 (s, 
1H), 4.32 (s, 2H), 3.86 (s, 3H), 2.38 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 157.58, 140.13, 
130.11, 121.13, 120.80, 111.52, 55.33, 50.01, 21.71. HRSM (ESI) m/z [M]+ for C9H12O2 
152.0837, found 152.0846.
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(9)—9 was synthesized following procedures detailed in refs 28 and 35. Yield 1.8 g (68%), 
white amorphous solid. 1H NMR (500 MHz, chloroform-d) δ 9.80 (s, 1H), 6.31 (s, 1H), 3.84 
(s, 3H), 2.96−2.92 (m, 2H), 2.80−2.74 (m, 2H), 1.02 (s, 9H), 0.95 (s, 9H), 0.23 (s, 6H), 0.21 
(s, 6H). 13C NMR (126 MHz, CDCl3) δ 201.47, 168.36, 153.48, 151.94, 138.10, 121.44, 
118.81, 110.15, 109.97, 52.69, 43.83, 26.00 (3C), 25.83 (3C), 18.74, 18.43, −3.96 (2C), 
−4.00 (2C). HRMS (ESI) m/z [M + H]+ for C23H40ClO5Si2 487.2103, found 487.2120.
Methyl 3-Chloro-2-(2-(1-(4-fluorobenzyl)-1H-imidazol-2-yl)ethyl)-4,6-
dihydroxybenzoate (10)—Yield 22 mg (21%), white amorphous solid. 1H NMR (500 
MHz, MeOD) δ 7.07−6.94 (m, 5H), 6.86 (d, J = 1.4 Hz, 1H), 6.29 (s, 1H), 5.00 (s, 2H), 3.69 
(s, 3H), 3.22−3.19 (m, 2H), 2.84 (m, 2H). 13C NMR (126 MHz, MeOD) δ 171.22, 164.76, 
162.81, 160.69, 158.81, 148.82, 141.37, 134.18, 130.01, 129.94, 127.28, 121.71, 116.75, 
116.58, 112.63 (d, J = 558.4 Hz), 103.34, 52.85, 31.45, 27.26. HRMS (ESI) m/z [M + H] for 
C20H19ClFN2O4 405.1017, found 405.1009.
Methyl 3-Chloro-2-(2-(1-(4-chlorobenzyl)-1H-imidazol-2-yl)-ethyl)-4,6-
dihydroxybenzoate (11)—Yield 28 mg, (25%), white amorphous solid. 1H NMR (500 
MHz, CDCl3, MeOD) δ 7.24 (d, J = 8.4 Hz, 2H), 6.98 (d, J = 1.4 Hz, 1H), 6.90 (d, J = 8.4 
Hz, 2H), 6.78 (d, J = 1.4 Hz, 1H), 6.40 (s, 1H), 4.97 (s, 2H), 3.81 (s, 3H), 3.46−3.40 (m, 
2H), 2.89−2.80 (m, 2H). 13C NMR (126 MHz, CDCl3, MeOD) δ 170.63, 162.31, 157.66, 
147.56, 141.56, 134.60, 134.02, 129.19 (2C), 127.92 (2C), 127.05, 120.00, 114.57, 106.08, 
102.68, 52.59, 30.87, 29.69, 26.04 HRMS (ESI) m/z [M + H] for C20H19Cl2N2O4 421.0722, 
found 421.0714.
Methyl 2-(2-(1-(4-Bromobenzyl)-1H-imidazol-2-yl)ethyl)-3-chloro-4,6-
dihydroxybenzoate (12)—Yield 45 mg (38%), off-white amorphous solid. 1H NMR (400 
MHz, CDCl3, MeOD) δ 7.36 (d, J = 8.4 Hz, 2H), 6.91 (d, J = 1.4 Hz, 1H), 6.82 (d, J = 8.5 
Hz, 2H), 6.77 (d, J = 1.5 Hz, 1H), 6.35 (s, 1H), 4.93 (s, 2H), 3.78 (s, 3H), 3.42−3.34 (m, 
2H), 2.84−2.77 (m, 2H). 13C NMR (101 MHz, CDCl3, MeOD) δ 170.23, 161.42, 157.64, 
147.25, 141.09, 134.83, 131.69 (2C), 127.85 (2C), 126.55, 121.59, 119.68, 114.27, 102.14, 
99.99, 52.03, 30.38, 25.69. HRMS (ESI) m/z [M + H]+ for C20H19BrClN2O4 465.0217, 
found 465.0237. tR = 4.17 min, 95.3%.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(4-iodobenzyl)-1H-imidazol-2-
yl)ethyl)benzoate (13)—Yield 22 mg (35%), white amorphous solid. 1H NMR (400 
MHz, CDCl3, MeOD): δ 7.59−7.57 (dd, J = 11.6 Hz, 2H), 7.14−7.11 (dd, J = 10.0 Hz, 2H), 
7.05 (s, 1H), 6.86 (s, 1H), 6.44 (s, 1H), 5.14 (s, 2H), 3.87 (s, 3H), 3.48−3.44 (t, J = 16.8, 
2H), 2.91−2.87 (t, J = 18.4 Hz, 2H.). 13C NMR (125 MHz, CDCl3, MeOD): δ 170.6, 162.4, 
157.6, 147.6, 141.5, 138.1, 128.4, 127.2, 120.0, 114.6, 106.1, 102.7, 93.6, 52.6, 52.2, 49.0, 
30.9, 26.1, 25.2, 20.1. HRMS (ESI) m/z [M + H]+ for C20H18ClIN2O4 513.0020, found 
513.0070.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(4-methylbenzyl)-1H-imidazol-2-
yl)ethyl)benzoate (14)—Yield 44 mg (43%), off-white amorphous solid. 1H NMR (500 
MHz, MeOD) δ 7.15 (d, J = 7.9 Hz, 2H), 7.03 (d, J = 1.4 Hz, 1H), 7.00−6.96 (m, 2H), 6.94 
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(d, J = 1.5 Hz, 1H), 6.39 (s, 1H), 5.05 (s, 2H), 3.77 (s, 3H), 3.37−3.30 (m, 2H), 2.97−2.89 
(m, 2H), 2.31 (s, 3H). 13C NMR(125 MHz, MeOD) δ 171.3, 160.9, 159.0, 148.8, 141.5, 
138.9, 135.1, 130.5 (2C), 127.9 (2C), 127.1, 121.8, 115.0, 110.1, 103.3, 52.8, 50.1, 31.5, 
27.3, 21.1. HRMS (ESI) m/z [M + H]+ for C21H22ClN2O4 401.1268, found 401.1266.
Methyl 3-Chloro-2-(2-(1-(4-ethylbenzyl)-1H-imidazol-2-yl)ethyl)-4,6-
dihydroxybenzoate (15)—Yield 37 mg (39%), off white amorphous solid. 1H NMR (500 
MHz, CDCl3, MeOD) δ 7.14 (d, J = 8.1 Hz, 2H), 7.11−7.08 (m, 1H), 6.98−6.91 (m, 2H), 
6.85 (d, J = 1.5 Hz, 1H), 6.44 (s, 1H), 4.96 (s, 3H), 3.54−3.45 (m, 2H), 3.04 (t, J = 7.9 Hz, 
2H), 2.59 (q, J = 7.6 Hz, 2H), 1.17 (td, J = 7.6, 1.0 Hz, 3H). 13C NMR (125 MHz, CDCl3, 
MeOD) δ 170.6, 162.1, 158.2, 147.2, 145.0, 140.9, 132.1, 128.8 (2C), 127.2 (2C), 124.2, 
120.6, 114.9, 106.2, 103.0, 50.0, 49.9, 30.7, 28.6, 25.6, 15.6. HRMS (ESI) m/z [M + H]+ for 
C22H24ClN2O4 415.1425, found 415.1432.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(4-isopropylbenzyl)-1H-imidazol-2-
yl)ethyl)benzoate (16)—Yield 25 mg (22%), white amorphous solid. 1H NMR (500 
MHz, CDCl3) δ 7.13 (d, J = 8.1 Hz, 2H), 7.03 (s, 1H), 6.90 (d, J = 8.2 Hz, 2H), 6.80 (d, J = 
1.5 Hz, 1H), 6.49 (s, 1H), 4.95 (s, 2H), 3.79 (s, 3H), 3.50 (t, J = 7.9 Hz, 2H), 3.00−2.92 (m, 
2H), 2.82 (hept, J = 6.9 Hz, 1H), 1.16 (d, J = 7.0 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 
170.63, 162.91, 157.32, 149.25, 147.18, 127.20 (2C), 126.81 (2C), 120.19, 114.50, 106.24, 
103.00, 99.98, 52.76, 49.56, 33.81, 30.77, 29.72, 23.93 (2C). HRMS (ESI) m/z [M + H]+ for 
C23H26ClN2O4 429.1581, found 429.1588.
Methyl 3-Chloro-2-(2-(1-(4-cyanobenzyl)-1H-imidazol-2-yl)-ethyl)-4,6-
dihydroxybenzoate (17)—Yield 37 mg (39%), off white amorphous solid. 1H NMR (500 
MHz, CDCl3) δ 7.79 (q, J = 7.8, 6.0 Hz, 2H), 7.61−7.36 (m, 2H), 7.20−7.12 (m, 1H), 7.05 
(s, 1H), 6.57 (s, 1H), 5.44−5.25 (m, 2H), 4.00 (s, 3H), 3.57 (q, J = 7.7 Hz, 2H), 3.02 (t, J = 
7.9 Hz, 2H). 13C NMR (125 MHz, CDCl3): 170.4, 161.5, 158.0, 147.8, 142.0, 141.2, 132.8, 
(2C), 127.7, 127.4, 127.0 (2C), 120.2, 118.2, 114.5, 111.6, 102.4, 52.4, 52.3, 30.8, 26.0. 
HRMS (ESI) m/z [M + H]+ for C21H19ClN3O4 412.1064, found 412.1049.
Methyl 3-Chloro-2-(2-(1-(4-ethynylbenzyl)-1H-imidazol-2-yl)-ethyl)-4,6-
dihydroxybenzoate (18)—Yield 37 mg (35%), tan amorphous solid. 1H NMR (500 MHz, 
CDCl3) δ 7.46 (d, J = 8.3 Hz, 1H), 7.06 (d, J = 1.4 Hz, 1H), 7.00 (d, J = 8.2 Hz, 1H), 6.86 (d, 
J = 1.4 Hz, 1H), 6.48 (s, 1H), 5.12 (s, 1H), 3.84 (s, 2H), 3.50 (dd, J = 9.3, 6.7 Hz, 1H), 3.09 
(s, 1H), 2.94 (dd, J = 9.0, 7.0 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 170.71, 162.73, 
158.41, 147.66, 141.27, 136.69, 132.78, 129.10, 126.79, 126.61, 126.52, 122.09, 120.19, 
120.15, 114.98, 105.65, 102.81, 82.85, 52.61, 49.28, 30.86, 26.01. HRMS (ESI) m/z [M + 
H]+ for C22H20ClN2O4 411.1112, found 411.1121.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(4-(trifluoromethyl)-benzyl)-1H-
imidazol-2-yl)ethyl)benzoate (19)—Yield 24 mg (36%), white amorphous solid. 1H 
NMR (400 MHz, CDCl3, MeOD): δ 7.56−7.55 (dd, J = 9.7 Hz, 2H), 7.15 (s, 1H), 7.10−7.08 
(dd, J = 11.3 Hz, 2H), 6.86 (s, 1H), 6.44 (s, 1H), 5.06 (s, 2H), 3.86 (s, 3H), 3.47−3.43 (t, J = 
16.3 Hz, 2H), 3.04−3.00 (t, J = 16.3 Hz, 2H). 13C NMR (125 MHz, CDCl3, MeOD) δ 170.2, 
162.1, 157.8, 147.3, 140.3, 138.7, 131.1, 130.8, 127.1, 126.3, 126.2, 124.7, 122.6, 120.5, 
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114.6, 111.4, 106.1, 103.1, 52.9, 30.6, 25.3. HRMS (ESI) m/z [M + H+] for 
C21H18ClF3N2O4 455.0937, found 455.0972.
Methyl 2-(2-(1-([1,1′-Biphenyl]-4-ylmethyl)-1H-imidazol-2-yl)-ethyl)-3-
chloro-4,6-dihydroxybenzoate (20)—Yield 35 mg (29%), tan amorphous solid. 1H 
NMR (500 MHz, CDCl3, MeOD) δ 7.54−7.48 (m, 4H), 7.39 (ddd, J = 8.0, 7.0, 1.7 Hz, 2H), 
7.31 (td, J = 7.2, 1.4 Hz, 1H), 7.07 (dd, J = 8.3, 1.6 Hz, 2H), 6.98 (s, 1H), 6.86 (s, 1H), 6.41 
(s, 1H), 5.07 (s, 2H), 3.83 (s, 3H), 3.52−3.45 (m, 2H), 2.92−2.87 (m, 2H). 13C NMR (126 
MHz, CDCl3) δ 170.80, 162.08, 157.84, 147.65, 141.83, 140.99, 140.24, 135.21, 128.81 
(2C), 127.62 (2C), 127.52, 127.16, 127.00 (2C), 126.98 (2C), 120.08, 114.67, 106.06, 
102.49, 52.50, 49.64, 30.89, 26.17. HRMS (ESI) m/z [M + H]+ for C26H23ClN2O4 
463.1425, found 463.1447.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(4-methoxybenzyl)-1H-imidazol-2-
yl)ethyl)benzoate (21)—Yield 25 mg (23%), tan amorphous solid. 1H NMR (400 MHz, 
CDCl3, MeOD) δ 6.86−6.84 (m, 1H), 6.82 (d, J = 1.4 Hz, 1H), 6.74−6.69 (m, 4H), 6.31 (s, 
1H), 4.85 (s, 2H), 3.72 (s, 3H), 3.65 (s, 3H), 3.38−3.32 (m, 2H), 2.82−2.76 (m, 2H). 13C 
NMR (126 MHz, CDCl3, MeOD) δ 174.64, 165.64, 163.22, 162.05, 151.40, 145.46, 135.37, 
132.06 (2C), 132.02, 130.37, 123.92, 118.20 (2C), 110.16, 106.36, 99.99, 59.12, 56.29, 
34.61, 30.03. HRMS (ESI) m/z [M–H]− for C21H21ClN2O5 415.1061, found 415.1061.
Methyl 3-Chloro-2-(2-(1-(3,4-dichlorobenzyl)-1H-imidazol-2-yl)-ethyl)-4,6-
dihydroxybenzoate (22)—Yield 27 mg (23%), tan amorphous solid. 1H NMR (400 MHz, 
CDCl3, MeOD) δ 7.30 (d, J = 8.3 Hz, 1H), 7.05 (d, J = 1.9 Hz, 2H), 6.92 (d, J = 1.7 Hz, 1H), 
6.81 (dd, J = 8.3, 2.2 Hz, 1H), 6.32 (s, 1H), 4.94 (s, 2H), 3.76 (s, 3H), 3.36−3.29 (m, 2H), 
2.95 (t, J = 7.8 Hz, 2H). 13C NMR (126 MHz, CDCl3, MeOD) δ 173.55, 164.94, 161.93, 
141.26, 137.43, 135.20, 133.07, 130.90, 130.47, 125.31 (2C), 118.43, 116.40, 110.96, 
107.00 (2C), 56.54, 53.05, 33.98, 28.86. HRMS (ESI) m/z [M + H]+ for C20H18Cl3N2O4 
455.0332, found 455.0354.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(naphthalen-1-ylmethyl)-1H-imidazol-2-
yl)ethyl)benzoate (23)—Yield 32 mg (28%), tan amorphous solid. 1H NMR (400 MHz, 
CDCl3, MeOD) δ 7.79 (dd, J = 6.8, 2.5 Hz, 1H), 7.71 (dd, J = 8.0, 3.9 Hz, 2H), 7.48−7.40 
(m, 2H), 7.28 (d, J = 1.2 Hz, 1H), 6.93 (d, J = 1.4 Hz, 1H), 6.72 (d, J = 1.5 Hz, 1H), 
6.71−6.67 (m, 1H), 6.32 (s, 1H), 5.43 (s, 2H), 3.73 (s, 3H), 3.45−3.35 (m, 2H), 2.94−2.84 
(m, 2H). 13C NMR (126 MHz, CDCl3, MeOD) δ 170.58, 161.56, 158.02, 147.88, 141.47, 
133.57, 131.62, 130.34, 128.92, 128.68, 126.80 (2C), 126.15, 125.35, 123.93, 121.99, 
120.36, 114.62, 106.32, 102.38, 52.29, 47.31, 30.74, 26.17. HRMS (ESI) m/z [M + H]+ for 
C24H21ClN2O4 437.1268, found 437.1250.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(naphthalen-2-ylmethyl)-1H-imidazol-2-
yl)ethyl)benzoate (24)—Yield 28 mg (25%), tan amorphous solid. 1H NMR (400 MHz, 
DMSO-d6) δ 7.88 (dd, J = 9.1, 4.0 Hz, 2H), 7.83−7.78 (m, 1H), 7.51−7.46 (m, 1H), 7.25 
(dd, J = 8.4, 1.9 Hz, 1H), 7.18 (d, J = 1.3 Hz, 1H), 6.85 (d, J = 1.3 Hz, 1H), 6.42 (s, 1H), 
5.29 (s, 2H), 3.57 (s, 3H), 2.92−2.86 (m, 2H), 2.77−2.71 (m, 2H). 13C NMR (126 MHz, 
DMSO-d6) δ 167.86, 155.00, 154.47, 146.42, 137.73, 135.17, 132.79, 132.21, 128.35, 
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127.60 (2C), 127.54, 126.80, 126.43 (2C), 126.04, 124.94, 124.84, 120.56, 113.74, 110.78, 
101.68, 51.80, 48.38, 29.92, 26.18. HRMS (ESI) m/z [M + H]+ for C24H21ClN2O4 
437.1268, found 437.1280.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(quinolin-5-ylmethyl)-1H-imidazol-2-
yl)ethyl)benzoate (25)—Yield 29 mg (25%), white amorphous solid. 1H NMR (500 
MHz, CDCl3, MeOD) δ 8.87 (dd, J = 4.3, 1.6 Hz, 1H), 8.20−8.16 (m, 1H), 8.00 (d, J = 8.5 
Hz, 1H), 7.60 (dd, J = 8.5, 7.2 Hz, 1H), 7.49−7.44 (m, 1H), 6.99 (s, 1H), 6.86−6.83 (m, 1H), 
6.76 (s, 1H), 6.36 (s, 1H), 5.48 (s, 2H), 3.83 (s, 3H), 3.48−3.44 (m, 2H), 2.95−2.89 (m, 
2H). 13C NMR (126 MHz, CDCl3) δ 170.55, 161.86, 157.87, 150.21, 147.86, 141.56, 
132.32, 131.06, 129.45, 129.37, 127.44, 125.58, 124.79, 121.64, 120.13, 114.59, 106.08, 
102.48, 99.99, 52.49, 46.63, 30.93, 26.20. HRMS (ESI) m/z [M + H]+ for C23H21ClN3O4 
438.1221, found 438.1207.
Methyl 3-Chloro-2-(2-(1-(3-fluorobenzyl)-1H-imidazol-2-yl)ethyl)-4,6-
dihydroxybenzoate (26)—Yield 26 mg (25%), pale-yellow amorphous solid. 1H NMR 
(500 MHz, CDCl3) δ 7.29−7.20 (m, 1H), 7.01 (d, J = 1.4 Hz, 1H), 6.92 (m, 1H), 6.82 (d, J = 
1.4 Hz, 1H), 6.75 (m, 1H), 6.70−6.58 (m, 1H), 6.46 (s, 1H), 5.01 (s, 2H), 3.80 (s, 3H), 
3.52−3.40 (m, 2H), 2.88−2.74 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 157.05, 147.61, 
141.78, 130.85, 127.79, 122.12, 120.22 (2C), 115.28, 115.12, 113.69, 113.51, 106.66, 
102.98 (2C), 100.13, 53.58, 48.96, 31.01, 26.26. HRMS (ESI) m/z [M + H] for 
C20H19ClFN2O4 405.1017, found 405.1009.
Methyl 3-Chloro-2-(2-(1-(3-chlorobenzyl)-1H-imidazol-2-yl)-ethyl)-4,6-
dihydroxybenzoate (27)—Yield 47 mg (44%), pale-yellow amorphous solid. 1H NMR 
(500 MHz, CDCl3, MeOD) δ 7.25−7.20 (m, 2H), 7.03 (d, J = 1.6 Hz, 1H), 6.99−6.96 (m, 
1H), 6.91−6.84 (m, 2H), 6.40 (s, 1H), 5.00 (s, 2H), 3.82 (s, 3H), 3.49−3.33 (m, 2H), 
3.01−2.83 (m, 2H). 13C NMR (125 MHz, CDCl3, MeOD) δ 170.6, 161.9, 158.2, 147.5, 
141.1, 137.7, 135.1, 130.5, 128.5, 126.8, 125.9, 124.9, 120.5, 114.8, 106.2, 102.7, 52.6 (2C), 
30.6, 25.8. HRMS (ESI) m/z [M + H]+ for C20H19Cl2N2O4 421.0722, found 421.0728.
Methyl 2-(2-(1-(3-Bromobenzyl)-1H-imidazol-2-yl)ethyl)-3-chloro-4,6-
dihydroxybenzoate (28)—Yield 23 mg (19%), white amorphous solid. 1H NMR (500 
MHz, CDCl3, MeOD) δ 7.38 (m, 1H), 7.19−7.09 (m, 2H), 6.99 (d, J = 1.5 Hz, 1H), 6.91 (m, 
1H), 6.84 (d, J = 1.5 Hz, 1H), 6.40 (s, 1H), 5.00 (s, 2H), 3.83 (s, 3H), 3.46−3.38 (m, 2H), 
2.92−2.79 (m, 2H). 13C NMR (126 MHz, CDCl3, MeOD) δ 168.02, 159.25, 155.49, 145.00, 
138.77, 135.70, 128.71, 128.01, 126.95, 124.05, 122.60, 120.52, 117.64, 112.15, 103.58, 
100.01, 49.95, 46.22, 28.09, 23.35. HRMS (ESI) m/z [M + H] for C20H19BrClN2O4 
465.0217, found 465.0225.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(3-iodobenzyl)-1H-imidazol-2-
yl)ethyl)benzoate (29)—Yield 4 mg (11%), white amorphous solid. 1H NMR (400 MHz, 
DMSO-d6): δ 7.67−7.64 (dd, J = 7.05 Hz, 1H), 7.43 (s, 1H), 7.18−7.14 (m, 2H), 7.08−7.06 
(dd, J = 9.24 Hz, 1H), 6.86 (s, 1H), 6.47 (s, 1H), 5.14 (s, 2H), 3.68 (s, 3H), 2.92−2.88 (t, J = 
16.3 Hz, 2H), 2.73−2.67 (t, J = 18.2 Hz, 2H). 13C NMR (125 MHz, DMSO-d6, MeOD): δ 
167.9, 155.0, 154.5, 146.4, 140.2, 137.7, 136.2, 135.1, 130.9, 126.0, 120.6, 113.8, 110.8, 
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101.8, 99.5, 95.2, 52.0, 47.4, 29.8, 26.1. HRMS (ESI) m/z [M + H+] for C20H18ClIN2O4 
513.0023, found 513.0065.
Methyl 2-(2-(1-(3-Methoxybenzyl)-1H-imidazol-2-yl)ethyl)-3-chloro-4,6-
dihydroxybenzoate (30)—Yield 32 mg (31%), white amorphous solid. 1H NMR (400 
MHz, CDCl3) δ 7.06 (s, 1H), 6.88 (s, 1H), 6.82 (d, J = 9.0 Hz, 1H), 6.62 (d, J = 7.7 Hz, 1H), 
6.55 (s, 1H), 6.53 (s, 1H), 5.04 (s, 2H), 3.85 (s, 3H), 3.76 (s, 3H), 3.59−3.51 (m, 2H), 
2.95−2.89 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 170.68, 162.88, 160.13, 157.00, 147.45, 
141.62, 137.81, 130.13, 127.12, 120.17, 118.69, 114.33, 113.03, 112.49, 106.43, 102.82, 
55.26, 52.64, 49.34, 30.90, 26.09. HRMS (ESI) m/z [M + H]+ for C21H22ClN2O5 417.1217, 
found 417.1221.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(3-methylbenzyl)-1H-imidazol-2-
yl)ethyl)benzoate (31)—Yield 18 mg (17%), tan amorphous solid. 1H NMR (500 MHz, 
CDCl3, MeOD) δ 7.06 (t, J = 7.6 Hz, 1H), 6.95 (d, J = 7.7 Hz, 1H), 6.85 (d, J = 1.5 Hz, 1H), 
6.75 (d, J = 1.5 Hz, 1H), 6.72−6.66 (m, 2H), 6.30 (s, 1H), 4.87 (s, 2H), 3.69 (s, 3H), 
3.36−3.30 (m, 2H), 2.81 (dd, J = 9.2, 6.9 Hz, 2H), 2.16 (s, 3H). 13C NMR (126 MHz, 
CDCl3, MeOD) δ 174.49, 165.52, 161.99, 151.39, 145.16, 142.73, 139.62, 132.79 (2C), 
131.28, 129.76, 127.67, 124.32, 118.57, 110.31, 106.43, 56.27, 53.48, 34.48, 29.85, 25.07. 
HRMS (ESI) m/z [M + H]+ for C21H22ClN2O4 401.1268, found 401.1255.
Methyl 2-(2-(1-([1,1′-Biphenyl]-3-ylmethyl)-1H-imidazol-2-yl)-ethyl)-3-
chloro-4,6-dihydroxybenzoate (32)—Yield 46 mg (39%), pale-yellow amorphous 
solid. 1H NMR (400 MHz, CDCl3, MeOD) δ 7.53−7.47 (m, 3H), 7.41 (dd, J = 9.1, 7.3 Hz, 
3H), 7.38−7.33 (m, 1H), 7.23 (s, 1H), 7.03 (d, J = 1.3 Hz, 1H), 6.99 (d, J = 7.8 Hz, 1H), 6.89 
(d, J = 1.4 Hz, 1H), 6.46 (s, 1H), 5.12 (s, 2H), 3.82 (s, 3H), 3.56−3.46 (m, 2H), 2.97−2.89 
(m, 2H). 13C NMR δ (100 MHz, CDCl3): 170.8, 163.0, 157.9, 147.7, 142.4, 141.5, 140.5, 
136.6, 129.8 (3C), 129.1(2C), 128.0, 127.3, 127.3, 125.7, 125.6, 120.5, 114.9, 106.3, 103.2, 
52.8, 49.9, 31.1, 26.2. HRMS (ESI) m/z [M − H]− for C26H22ClN2O4 461.1268, found 
461.1259.
Methyl 3-Chloro-2-(2-(1-(2-fluorobenzyl)-1H-imidazol-2-yl)ethyl)-4,6-
dihydroxybenzoate (33)—Yield 23 mg (22%), white amorphous solid. 1H NMR (500 
MHz, CDCl3, MeOD) δ 7.27−7.23 (m, 1H), 7.06−6.98 (m, 2H), 6.94 (d, J = 1.4 Hz, 1H), 
6.81 (d, J = 1.4 Hz, 1H), 6.78 (dd, J = 7.5, 1.7 Hz, 1H), 6.40 (s, 1H), 5.05 (s, 2H), 3.82 (s, 
3H), 3.64−3.38 (m, 2H), 3.05−2.68 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 170.80, 
162.21, 157.79, 147.67, 141.77, 130.04, 128.42, 127.27, 124.63, 123.62, 123.50, 119.93, 
115.60 (d, J = 21.0 Hz), 114.66, 106.02, 102.55, 52.51, 43.46, 30.83, 26.04. HRMS (ESI) 
m/z [M + H] for C20H18ClFN2O4 405.1029, found 405.1017.
Methyl 2-(2-(1-(2-Chlorobenzyl)-1H-imidazol-2-yl)ethyl)-3-chloro-4,6-
dihydroxybenzoate (34)—Yield 23 mg (21%), white amorphous solid. 1H NMR (500 
MHz, CDCl3, MeOD) δ 7.27 (s, 1H), 7.24−7.16 (m, 2H), 7.01 (d, J = 1.6 Hz, 1H), 6.94 (dd, 
J = 1.9, 1.0 Hz, 1H), 6.84 (m, 2H), 6.38 (s, 1H), 4.98 (s, 2H), 3.80 (s, 3H), 3.45−3.35 (m, 
2H), 2.94−2.85 (m, 2H). 13C NMR (126 MHz, CDCl3, MeOD) δ 170.58, 162.43, 157.43, 
147.63, 141.17, 133.48, 132.58, 129.83, 129.62, 127.72, 127.52, 126.18, 120.16, 114.51, 
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106.20, 102.85, 52.73, 47.48, 30.89, 25.78. HRMS (ESI) m/z [M + H]+ for C20H19Cl2N2O4 
421.0722, found 421.0714.
Methyl 2-(2-(1-(2-Bromobenzyl)-1H-imidazol-2-yl)ethyl)-3-chloro-4,6-
dihydroxybenzoate (35)—Yield 26 mg (22%), white amorphous solid. 1H NMR (500 
MHz, CDCl3) δ 7.54 (dd, J = 8.0, 1.3 Hz, 1H), 7.24−7.20 (m, 1H), 7.15 (td, J = 7.7, 1.7 Hz, 
1H), 7.10 (d, J = 1.6 Hz, 1H), 6.78 (d, J = 1.6 Hz, 1H), 6.67−6.57 (m, 1H), 6.48 (s, 1H), 5.06 
(s, 2H), 3.85 (s, 3H), 3.48−3.33 (m, 2H), 3.06−2.89 (m, 2H). 13C NMR (126 MHz, CDCl3) 
δ 170.47, 162.64, 157.77, 147.55, 140.60, 133.23 (2C), 130.08, 128.23 (2C), 122.57, 120.27 
(2C), 114.71, 105.94, 103.08, 52.85, 50.15, 30.78, 25.58. HRMS (ESI) m/z [M + H] for 
C20H19BrClN2O4 465.0217, found 465.0231.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(2-methylbenzyl)-1H-imidazol-2-
yl)ethyl)benzoate (36)—Yield 32 mg (31%), tan amorphous solid. 1H NMR (500 MHz, 
CDCl3, MeOD) δ 7.25 (s, 1H), 7.08−7.02 (m, 2H), 6.88−6.83 (m, 1H), 6.66−6.58 (m, 1H), 
6.47 (t, J = 6.7 Hz, 1H), 6.29 (s, 1H), 4.87 (s, 2H), 3.72 (s, 3H), 3.35−3.25 (m, 2H), 2.81 (dd, 
J = 10.9, 5.1 Hz, 2H), 2.10 (s, 3H). 13C NMR (126 MHz, CDCl3, MeOD) δ 174.43, 165.45, 
161.97, 151.53, 145.12, 139.32, 137.71, 134.49, 132.09, 130.45, 130.31, 129.87, 124.09, 
118.52, 110.38, 106.41, 56.28, 51.65, 34.50, 29.86, 22.59. HRMS (ESI) m/z [M + H]+ for 
C21H22ClN2O4 401.1268, found 401.1261.
Methyl 2-(2-(1-(2-Aminobenzyl)-1H-imidazol-2-yl)ethyl)-3-chloro-4,6-
dihydroxybenzoate (37)—Yield 20 mg (19%), white amorphous solid. 1H NMR (500 
MHz, MeOD) δ 7.07 (td, J = 7.8, 1.6 Hz, 1H), 6.98 (dd, J = 7.8, 1.4 Hz, 2H), 6.78 (dd, J = 
8.0, 1.2 Hz, 1H), 6.65 (td, J = 7.5, 1.2 Hz, 1H), 6.52 (dd, J = 7.6, 1.5 Hz, 1H), 6.39 (s, 1H), 
5.03 (s, 2H), 3.79 (s, 3H), 3.37−3.33 (m, 2H), 3.01−2.96 (m, 2H). 13C NMR (126 MHz, 
MeOD) δ 169.90, 159.44, 157.47, 147.55, 145.00, 140.02, 128.56, 127.00, 125.07, 120.41, 
120.32, 117.92, 116.00, 113.55, 108.77, 101.92, 51.46, 45.78, 29.89, 25.71. HRMS (ESI) 
m/z [M + H] for C20H20ClN3O4 402.1221, found 402.1230.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(2-methoxybenzyl)-1H-imidazol-2-
yl)ethyl)benzoate (38)—Yield 46 mg (42%), tan amorphous solid. 1H NMR (500 MHz, 
CDCl3) δ 7.26−7.23 (m, 1H), 6.97 (d, J = 1.4 Hz, 1H), 6.89−6.84 (m, 2H), 6.83 (d, J = 1.4 
Hz, 1H), 6.70 (dd, J = 7.8, 1.7 Hz, 1H), 6.44 (s, 1H), 5.03 (s, 2H), 3.84 (s, 3H), 3.81 (s, 3H), 
3.49−3.44 (m, 2H), 2.94−2.90 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 170.96, 162.35, 
157.84, 156.56, 147.74, 141.91, 129.33, 127.59, 126.69, 124.66, 120.72, 120.13, 114.71, 
110.27, 105.90, 102.51, 55.27, 52.50, 44.85, 30.85, 26.04. HRMS (ESI) m/z [M + H]+ for 
C21H22ClN2O5 417.1217, found 417.1211.
Methyl 3-Chloro-2-(2-(1-(2-ethylbenzyl)-1H-imidazol-2-yl)ethyl)-4,6-
dihydroxybenzoate (39)—Yield 33 mg (31%), tan amorphous solid. 1H NMR (400 MHz, 
CDCl3, MeOD) δ 7.43 (d, J = 2.1 Hz, 1H), 7.40 (d, J = 3.0 Hz, 1H), 7.32−7.28 (m, 1H), 7.26 
(d, J = 7.7 Hz, 1H), 6.83 (d, J = 7.7 Hz, 1H), 6.79 (s, 1H), 6.55 (s, 1H), 4.98 (s, 2H), 4.02 (s, 
3H), 3.68 (t, J = 7.3 Hz, 2H), 3.45 (t, J = 7.1 Hz, 3H), 2.52 (q, J = 7.5 Hz, 3H), 1.19 (t, J = 
7.6 Hz, 3H). 13C NMR (126 MHz, CDCl3, MeOD) δ 169.85, 161.95, 158.20, 146.18, 
145.33, 142.11, 138.91, 129.92, 129.32, 128.17, 127.04, 120.75, 119.05, 114.84, 106.28, 
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103.49, 53.17, 30.86, 30.04, 25.20, 24.25, 14.49. HRMS (ESI) m/z [M + H]+ for 
C22H24ClN2O4 415.1425, found 415.1419. tR = 4.27 min, 95.3%.
Methyl 3-Chloro-2-(2-(1-(2-ethoxybenzyl)-1H-imidazol-2-yl)-ethyl)-4,6-
dihydroxybenzoate (40)—Yield 44 mg (39%), tan amorphous solid. 1H NMR (400 MHz, 
CDCl3, MeOD) δ 7.18 (t, J = 8.0 Hz, 1H), 6.88 (d, J = 1.9 Hz, 1H), 6.83−6.76 (m, 3H), 6.67 
(d, J = 7.6 Hz, 1H), 6.38 (s, 1H), 4.99 (s, 2H), 3.97 (q, J = 7.7, 6.8 Hz, 2H), 3.80 (s, 3H), 
3.45−3.39 (m, 2H), 2.88 (t, J = 8.1 Hz, 2H), 1.32 (t, J = 6.8 Hz, 3H). 13C NMR (126 MHz, 
CDCl3, MeOD) δ 170.97, 162.15, 157.97, 155.99, 147.73, 141.95, 129.25, 127.68, 126.65, 
124.63, 120.46, 120.13, 114.73, 111.01, 105.90, 102.43, 63.51, 52.45, 44.95, 30.86, 26.12, 
14.69. HRMS (ESI) m/z [M + H]+ for C22H24ClN2O5 431.1374, found 431.1378. tR = 2.71 
min, 98.3%.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(2-isopropoxybenzyl)-1H-imidazol-2-
yl)ethyl)benzoate (41)—Yield 18 mg (16%), tan amorphous solid. 1H NMR (400 MHz, 
CDCl3, MeOD) δ 7.21 (t, J = 8.0 Hz, 1H), 6.95 (s, 1H), 6.86−6.78 (m, 3H), 6.72 (d, J = 7.5 
Hz, 1H), 6.44 (s, 1H), 5.00 (s, 2H), 4.56 (hept, J = 10.8, 5.3 Hz, 1H), 3.85 (s, 3H), 3.52−3.45 
(m, 2H), 2.97−2.87 (m, 2H), 1.27 (d, J = 6.0 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 
170.97, 162.15, 157.97, 156.00, 147.73, 141.95, 129.25, 127.68, 126.65, 124.63, 120.46, 
120.13, 114.73, 111.01, 105.90, 102.43, 99.99, 63.51, 52.45, 44.95, 30.86, 26.12, 14.69. 
HRMS (ESI) m/z [M + H]+ for C23H26ClN2O5 445.1530, found 445.1521. tR = 2.70 min, 
97.7%.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(2-propoxybenzyl)-1H-imidazol-2-
yl)ethyl)benzoate (42)—Yield 34 mg (29%), tan amorphous solid. 1H NMR (500 MHz, 
CDCl3) δ 7.29−7.26 (m, 1H), 7.02 (d, J = 1.4 Hz, 1H), 6.90−6.85 (m, 3H), 6.76−6.73 (m, 
1H), 6.49 (s, 1H), 5.10 (s, 2H), 3.95 (t, J = 6.5 Hz, 2H), 3.84 (s, 3H), 3.56−3.50 (m, 2H), 
3.03−2.96 (m, 2H), 1.80 (qt, J = 7.4, 6.5 Hz, 2H), 1.01 (t, J = 7.4 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 170.91, 162.91, 157.83, 156.11, 147.58, 141.58, 129.36, 127.76, 126.49, 
124.55, 120.56, 120.15, 114.73, 111.04, 105.90, 102.72, 69.53, 52.55, 45.00, 30.85, 26.04, 
22.57, 10.61. HRMS (ESI) m/z [M + H]+ for C23H26ClN2O5 445.1530, found 445.1539. tR 
= 2.73 min, 98.0%.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(2-(trifluoromethyl)-benzyl)-1H-
imidazol-2-yl)ethyl)benzoate (43)—Yield 25 mg (21%), white amorphous solid. 1H 
NMR (400 MHz, CDCl3, MeOD) δ 7.65 (d, J = 7.7 Hz, 1H), 7.43 (t, J = 7.6 Hz, 1H), 7.36 (t, 
J = 7.7 Hz, 1H), 7.02 (s, 1H), 6.79 (s, 1H), 6.57 (d, J = 7.8 Hz, 1H), 6.39 (s, 1H), 5.25 (s, 
2H), 3.85 (s, 3H), 3.50−3.41 (m, 2H), 2.93−2.79 (m, 2H). 13C NMR (126 MHz, CDCl3, 
MeOD) δ 170.72, 162.08, 157.95, 148.07, 141.52, 134.95, 132.62, 127.97, 127.61, 126.91, 
126.26 (q, J = 5.6 Hz), 125.20, 123.03, 120.21, 114.70, 105.88, 102.50, 52.46, 45.88, 30.87, 
25.83. HRMS (ESI) m/z [M + H]+ for C21H19ClF3N2O4 455.0985, found 455.0979.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(2-methoxy-4-methylbenzyl)-1H-
imidazol-2-yl)ethyl)benzoate (44)—Yield 45 mg (40%), tan amorphous solid. 1H NMR 
(400 MHz, CDCl3, MeOD) δ 7.28 (d, J = 2.1 Hz, 1H), 6.94 (d, J = 7.6 Hz, 1H), 6.85 (d, J = 
2.1 Hz, 1H), 6.76 (d, J = 7.3 Hz, 1H), 6.69 (s, 1H), 6.56 (s, 1H), 4.81 (s, 2H), 3.99 (s, 3H), 
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3.74 (s, 3H), 3.63 (t, J = 7.4 Hz, 2H), 3.44 (t, J = 7.4 Hz, 2H), 2.34 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 169.87, 161.98, 157.11, 151.39, 145.68, 142.01, 140.11, 129.96, 129.53, 
121.73, 121.63, 120.51, 118.55, 112.14, 111.93, 55.44, 54.21, 46.62, 30.48, 29.73, 23.96, 
21.75. HRMS (ESI) m/z [M + H]+ for C22H24ClN2O5 431.1374, found 431.1370.
Methyl 3-Chloro-2-(2-(1-(furan-3-ylmethyl)-1H-imidazol-2-yl)-ethyl)-4,6-
dihydroxybenzoate (45)—Yield 40 mg (41%), off-white amorphous solid. 1H NMR (500 
MHz, CDCl3, MeOD) δ 7.30 (d, J = 1.6 Hz, 1H), 7.20 (s, 1H), 6.84 (dd, J = 2.7, 1.4 Hz, 
1H), 6.78 (d, J = 1.4 Hz, 1H), 6.36 (d, J = 2.0 Hz, 1H), 6.15 (d, J = 1.9 Hz, 1H), 4.80 (s, 2H), 
3.78 (d, J = 1.9 Hz, 3H), 3.39 (tt, J = 8.9, 2.5 Hz, 2H), 2.95−2.80 (m, 2H). 13C NMR (125 
MHz, CDCl3, MeOD): δ 170.8, 161.8, 158.1, 147.3, 144.1, 141.6, 141.6, 140.1, 126.7, 
121.0, 119.6, 114.7, 109.4, 106.2, 102.5, 52.4, 41.0, 30.8, 26.1. HRMS (ESI) m/z [M + H]+ 
for C18H18ClN2O5 377.0904, found 377.0905.
Methyl 3-Chloro-2-(2-(1-(furan-2-ylmethyl)-1H-imidazol-2-yl)-ethyl)-4,6-
dihydroxybenzoate (46)—Yield 44 mg (45%), off-white amorphous solid. 1H NMR (500 
MHz, CDCl3, MeOD) δ 7.31 (dt, J = 2.4, 1.2 Hz, 1H), 6.87 (dd, J = 2.4, 1.4 Hz, 1H), 6.83 
(d, J = 1.5 Hz, 1H), 6.40 (d, J = 1.8 Hz, 1H), 6.26 (dt, J = 3.5, 1.7 Hz, 1H), 6.18 (d, J = 3.3 
Hz, 1H), 4.94 (d, J = 1.6 Hz, 2H), 3.82 (d, J = 1.9 Hz, 3H), 3.46 (ddd, J = 10.2, 6.1, 2.0 Hz, 
2H), 2.95 (ddd, J = 9.8, 5.9, 1.5 Hz, 2H). 13C NMR (125 MHz, CDCl3, MeOD) δ 170.9, 
162.0, 158.2, 149.1, 147.4, 143.2, 141.8, 126.9, 119.7, 114.8, 110.6, 108.8, 106.2, 102.6, 
52.6, 42.6, 30.8, 26.1. HRMS (ESI) m/z [M + H]+ for C18H18ClN2O5 377.0904, found 
377.0911.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-((5-methylfuran-2-yl)-methyl)-1H-
imidazol-2-yl)ethyl)benzoate (47)—Yield 46 mg (46%), off white amorphous solid. 1H 
NMR (400 MHz, CDCl3, MeOD) δ 6.87 (d, J = 1.4 Hz, 1H), 6.84 (d, J = 1.4 Hz, 1H), 6.41 
(s, 1H), 6.08 (d, J = 3.1 Hz, 1H), 5.84 (dd, J = 3.0, 1.2 Hz, 1H), 4.88 (s, 2H), 3.84 (s, 3H), 
3.49−3.42 (m, 2H), 3.08−2.93 (m, 2H), 2.18 (d, J = 1.0 Hz, 3H). 13C NMR (125 MHz, 
CDCl3, MeOD) δ 171.0, 162.2, 158.3, 153.1, 147.3, 147.1, 141.9, 126.7, 119.7, 114.9, 
109.7, 106.5, 106.1, 102.6, 52.6, 42.7, 30.9, 26.2, 13.5. HRMS (ESI) m/z [M + H]+ for 
C19H20ClN2O5 391.1061, found 391.1066. tR = 3.05 min, 95.1%.
Methyl 3-Chloro-2-(2-(1-((5-chlorofuran-2-yl)methyl)-1H-imidazol-2-
yl)ethyl)-4,6-dihydroxybenzoate (48)—Yield 50 mg (47%), white amorphous solid. 1H 
NMR (400 MHz, CDCl3, MeOD) δ 6.91 (s, 2H), 6.31 (s, 1H), 6.23 (d, J = 3.4 Hz, 1H), 5.98 
(d, J = 3.3 Hz, 1H), 4.87 (s, 2H), 3.73 (s, 3H), 3.37−3.27 (m, 2H), 2.99 (t, J = 7.9 Hz, 
2H). 13C NMR (126 MHz, CDCl3, MeOD) δ 173.88, 165.00, 161.93, 151.08, 150.68, 
143.82, 141.62, 124.59, 118.45, 116.26, 111.28 (2C), 106.80 (2C), 56.40, 46.86, 34.09, 
29.14. HRMS (ESI) m/z [M + H]+ for C18H17Cl2N2O5 411.0515, found 411.0527. tR = 4.15 
min, 95.5%.
Methyl 3-Chloro-2-(2-(1-((3,5-dimethylfuran-2-yl)methyl)-1H-imidazol-2-
yl)ethyl)-4,6-dihydroxybenzoate (49)—Yield 36 mg (25%), off-white amorphous solid. 
1H NMR (400 MHz, CDCl3, MeOD) δ 7.28 (d, J = 2.0 Hz, 1H), 6.92 (s, 1H), 6.44 (s, 1H), 
5.77 (s, 1H), 4.80 (s, 2H), 3.89 (s, 3H), 3.59−3.48 (m, 2H), 3.37 (t, J = 7.1 Hz, 2H), 2.11 (s, 
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3H), 1.92 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 169.87, 161.98, 157.11, 151.39, 145.68, 
140.11, 129.96, 121.63, 120.51, 118.85, 118.55, 112.14, 111.93, 55.44, 54.21, 46.62, 30.48, 
29.73, 23.96, 21.75. HRMS (ESI) m/z [M + H]+ for C20H22ClN2O5 405.1217, found 
405.1210. tR = 3.24 min, 95.5%.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(thiophen-2-ylmethyl)-1H-imidazol-2-
yl)ethyl)benzoate (50)—Yield 37 mg (37%), yellow amorphous solid. 1H NMR (400 
MHz, CDCl3, MeOD) δ 7.23 (dd, J = 5.1, 1.3 Hz, 1H), 6.95 (d, J = 1.5 Hz, 1H), 6.92 (dd, J 
= 5.1, 3.5 Hz, 1H), 6.87 (dd, J = 3.5, 1.9 Hz, 2H), 6.43 (s, 1H), 5.17 (d, J = 0.9 Hz, 2H), 3.84 
(s, 3H), 3.56−3.44 (m, 2H), 3.01−2.92 (m, 2H). 13C NMR (125 MHz, CDCl3, MeOD) δ 
170.9, 162.1, 158.2, 147.3, 141.7, 138.5, 127.2, 126.9, 126.4, 126.2, 119.7, 114.9, 106.2, 
102.7, 52.6, 44.7, 30.9, 26.2. HRMS (ESI) m/z [M + H]+ for C18H18ClN2O4S 393.0676, 
found 393.0674.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(thiophen-3-ylmethyl)-1H-imidazol-2-
yl)ethyl)benzoate (51)—Yield 28 mg (27%), yellow amorphous solid. 1H NMR (400 
MHz, CDCl3, MeOD) δ 7.25 (d, J = 4.8 Hz, 1H), 6.98−6.92 (m, 2H), 6.83 (d, J = 1.5 Hz, 
1H), 6.81−6.78 (m, 1H), 6.37 (s, 1H), 4.97 (s, 2H), 3.79 (s, 3H), 3.43−3.37 (m, 2H), 
2.95−2.88 (m, 2H). 13C NMR (126 MHz, CDCl3, MeOD) δ 174.48, 165.67, 162.02, 151.06, 
145.03, 140.31, 131.26, 130.04, 129.39, 126.69, 124.00, 118.61, 110.15, 106.53, 56.40, 
49.27, 34.49, 29.68. HRMS (ESI) m/z [M + H]+ for C18H18ClN2O4S 393.0676, found 
393.0693.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-((5-methylthiophen-2-yl)-methyl)-1H-
imidazol-2-yl)ethyl)benzoate (52)—Yield 23 mg (22%), off-white amorphous solid. 1H 
NMR (400 MHz, CDCl3, MeOD) δ 7.34 (d, J = 1.8 Hz, 1H), 7.02−6.96 (m, 1H), 6.79 (d, J = 
4.1 Hz, 1H), 6.60 (d, J = 2.7 Hz, 1H), 6.48 (s, 1H), 5.03 (s, 2H), 3.95 (s, 3H), 3.58 (t, J = 7.2 
Hz, 2H), 3.39 (t, J = 7.2 Hz, 2H), 2.41 (s, 3H). 13C NMR (126 MHz, CDCl3, MeOD) δ 
169.83, 161.87, 158.19, 145.63, 138.77, 131.10, 129.14 (2C), 125.60 (2C), 120.60, 119.05, 
106.34, 103.54, 53.15, 46.03, 30.05, 24.21, 15.28. HRMS (ESI) m/z [M + H]+ for 
C19H20ClN2O4S 407.0832, found 407.0839.
Methyl 3-Chloro-2-(2-(1-((5-chlorothiophen-2-yl)methyl)-1H-imidazol-2-
yl)ethyl)-4,6-dihydroxybenzoate (53)—Yield 20 mg (18%), yellow amorphous 
solid. 1H NMR (500 MHz, CDCl3, MeOD) δ 6.95 (s, 1H), 6.87 (s, 1H), 6.68 (d, J = 3.5 Hz, 
1H), 6.63 (d, J = 3.5 Hz, 1H), 6.37 (s, 1H), 5.03 (s, 2H), 3.81 (s, 3H), 3.47−3.37 (m, 2H), 
3.02−2.92 (m, 2H). 13C NMR (126 MHz, CDCl3, MeOD) δ 174.29, 165.57, 162.00, 150.88, 
144.73, 140.23, 134.89, 130.21, 130.09, 129.35, 123.74, 118.59, 110.29, 106.65, 56.47, 
48.84, 34.48, 29.63. HRMS (ESI) m/z [M + H]+ for C18H17Cl2N2O4S 427.0286, found 
427.0292.
Methyl 3-Chloro-2-(2-(1-((4-chlorothiophen-2-yl)methyl)-1H-imidazol-2-
yl)ethyl)-4,6-dihydroxybenzoate (54)—Yield 23 mg (21%), tan amorphous solid. 1H 
NMR (400 MHz, CDCl3, MeOD) δ 6.97 (s, 1H), 6.90 (s, 1H), 6.83 (s, 1H), 6.67 (s, 1H), 
6.38 (s, 1H), 5.07 (s, 2H), 3.81 (s, 3H), 3.45−3.39 (m, 2H), 2.88 (t, J = 8.2 Hz, 2H). 13C 
NMR (126 MHz, CDCl3, MeOD) δ 170.61, 161.82, 158.12, 147.29, 141.48, 139.55, 127.34, 
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126.18, 125.05, 120.14, 119.50, 114.71, 106.03, 102.51, 52.44, 44.42, 30.76, 26.05. HRMS 
(ESI) m/z [M + H]+ for C18H17Cl2N2O4S 427.0286, found 427.0290.
Methyl 3-Chloro-2-(2-(1-((3-chlorothiophen-2-yl)methyl)-1H-imidazol-2-
yl)ethyl)-4,6-dihydroxybenzoate (55)—Yield 17 mg (15%), tan amorphous solid. 1H 
NMR (400 MHz, CDCl3, MeOD) δ 7.21 (dd, J = 5.9, 2.3 Hz, 1H), 6.90 (d, J = 2.1 Hz, 1H), 
6.86 (dt, J = 5.2, 1.8 Hz, 2H), 6.41 (s, 1H), 5.09 (s, 2H), 3.84 (s, 3H), 3.54−3.45 (m, 2H), 
2.96 (dd, J = 11.9, 5.4 Hz, 2H). 13C NMR (126 MHz, CDCl3, MeOD) δ 170.79, 162.08, 
158.04, 147.22, 141.70, 131.26, 127.92, 127.32, 125.17, 124.20, 119.32, 114.80, 105.96, 
102.55, 52.52, 42.02, 30.79, 26.15. HRMS (ESI) m/z [M + H]+ for C18H16Cl2N2O4S 
427.0286, found 427.0278.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(isoxazol-5-ylmethyl)-1H-imidazol-2-
yl)ethyl)benzoate (56)—Yield 15 mg (15%), tan amorphous solid. 1H NMR (400 MHz, 
CDCl3, MeOD) δ 8.17 (s, 1H), 6.96 (s, 1H), 6.89 (s, 1H), 6.42 (s, 1H), 6.04 (s, 1H), 5.17 (s, 
2H), 3.88 (s, 3H), 3.50−3.41 (m, 2H), 2.97−2.89 (m, 2H). 13C NMR (126 MHz, CDCl3, 
MeOD) δ 170.55, 166.32, 157.95, 150.41, 147.60, 141.46, 127.82, 119.70, 114.64, 106.11, 
102.64, 102.47, 102.14, 52.57, 41.22, 30.85, 25.99. HRMS (ESI) [M + H]+ for 
C17H17ClN3O5 378.0857, found 378.0866.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(thiazol-2-ylmethyl)-1H-imidazol-2-
yl)ethyl)benzoate (57)—Yield 41 mg (40%), tan amorphous solid. 1H NMR (400 MHz, 
CDCl3, MeOD) δ 7.72 (d, J = 3.2 Hz, 1H), 7.30 (d, J = 3.3 Hz, 1H), 6.99 (s, 1H), 6.95 (s, 
1H), 6.43 (s, 1H), 5.35 (s, 2H), 3.87 (s, 3H), 3.51−3.46 (m, 2H), 2.98−2.91 (m, 2H). 13C 
NMR (126 MHz, CDCl3, MeOD) δ 170.72, 165.84, 162.13, 157.91, 147.63, 143.06, 141.59, 
127.84, 120.27, 119.78, 114.71, 106.01, 102.63, 52.57, 46.84, 30.83, 26.06. HRMS (ESI) 
m/z [M + H]+ for C17H17ClN3O4S 394.0628, found 394.0630.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-((3-vinylthiophen-2-yl)-methyl)-1H-
imidazol-2-yl)ethyl)benzoate (58)—Yield 35 mg (32%), tan amorphous solid. 1H NMR 
(400 MHz, CDCl3, MeOD) δ 7.19 (d, J = 5.3 Hz, 1H), 7.15 (d, J = 5.3 Hz, 1H), 7.01 (s, 1H), 
6.77 (s, 1H), 6.58 (dd, J = 17.3, 10.9 Hz, 1H), 6.45 (s, 1H), 5.56 (d, J = 17.3 Hz, 1H), 5.31 
(d, J = 11.0 Hz, 1H), 5.11 (s, 2H), 3.87 (s, 3H), 3.58−3.49 (m, 2H), 3.07 (t, J = 7.8 Hz, 
2H). 13C NMR (126 MHz, CDCl3) δ 170.94, 163.17, 156.14, 142.75, 140.72, 139.77, 
138.46, 130.54, 128.69, 128.46, 126.69, 126.54, 126.04, 113.85, 106.68, 102.61, 52.59, 
38.44, 33.98, 32.45. HRMS (ESI) m/z [M + H]+ for C20H20ClN2O4S 419.0832, found 
419.0844.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-((3-vinylfuran-2-yl)-methyl)-1H-
imidazol-2-yl)ethyl)benzoate (59)—Yield 35 mg (33%), off-white amorphous solid. 1H 
NMR (400 MHz, CDCl3, MeOD) δ 7.30 (d, J = 2.0 Hz, 1H), 6.84 (d, J = 1.8 Hz, 1H), 6.51 
(d, J = 2.0 Hz, 1H), 6.49 (s, 1H), 6.48−6.41 (m, 1H), 5.50 (d, J = 17.3 Hz, 1H), 5.26 (d, J = 
11.0 Hz, 1H), 4.94 (s, 2H), 3.91 (s, 3H), 3.59 (t, J = 7.6 Hz, 2H), 3.22 (t, J = 7.7 Hz, 
2H). 13C NMR (126 MHz, CDCl3) δ 170.35, 162.14, 157.96, 146.62, 143.64 (2C), 124.53 
(2C), 123.65, 119.92 (2C), 116.57, 114.78, 108.33 (2C), 108.24, 106.19, 103.08, 52.84, 
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41.07, 30.43, 25.17. HRMS (ESI) m/z [M + H]+ for C20H20ClN2O5 403.1061, found 
403.1069.
Methyl 3-Chloro-2-(2-(1-((3-ethylthiophen-2-yl)methyl)-1H-imidazol-2-
yl)ethyl)-4,6-dihydroxybenzoate (60)—Yield 43 mg (39%), tan amorphous solid. 1H 
NMR (500 MHz, CDCl3, MeOD) δ 7.16 (d, J = 5.2 Hz, 1H), 6.91 (d, J = 1.4 Hz, 1H), 6.86 
(d, J = 5.2 Hz, 1H), 6.73 (d, J = 1.5 Hz, 1H), 6.45 (s, 1H), 5.04 (s, 2H), 3.86 (s, 3H), 
3.56−3.50 (m, 2H), 3.00−2.95 (m, 2H), 2.53 (q, J = 7.6 Hz, 2H), 1.12 (t, J = 7.6 Hz, 
3H). 13C NMR (126 MHz, CDCl3) δ 170.80, 162.20, 157.88, 147.06, 142.21, 141.84, 
130.82, 128.69, 126.96, 124.60, 119.11, 114.70, 106.03, 102.57, 52.57, 42.34, 30.78, 26.25, 
21.49, 14.92. HRMS (ESI) m/z [M + H]+ for C20H22ClN2O4S 421.0989, found 421.0995.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(pyridin-2-ylmethyl)-1H-imidazol-2-
yl)ethyl)benzoate (61)—Yield 15 mg (15%), tan amorphous solid. 1H NMR (400 MHz, 
CDCl3) δ 8.57 (d, J = 5.0 Hz, 1H), 7.68 (td, J = 7.7, 1.9 Hz, 1H), 7.13 (d, J = 1.5 Hz, 1H), 
6.99 (d, J = 1.6 Hz, 1H), 6.89 (d, J = 7.9 Hz, 1H), 6.51 (s, 1H), 5.23 (s, 2H), 3.89 (s, 3H), 
3.52 (t, J = 7.9 Hz, 2H), 3.05 (t, J = 8.0 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 170.50, 
162.80, 157.65, 149.98 (2C), 147.44, 137.50 (3C), 123.42, 121.11, 120.70, 114.63, 106.01, 
103.24, 52.94, 51.53, 30.62, 25.40. HRMS (ESI) m/z [M–H]− for C19H18ClN3O4 386.0908, 
found 386.0899.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(pyridin-3-ylmethyl)-1H-imidazol-2-
yl)ethyl)benzoate (62)—Yield 25 mg (25%), yellow amorphous solid. 1H NMR (500 
MHz, CDCl3, MeOD) δ 8.44 (d, J = 4.3 Hz, 1H), 8.30 (s, 1H), 7.32 (d, J = 6.0 Hz, 1H), 
7.31−7.24 (m, 1H), 6.98 (s, 1H), 6.83 (s, 1H), 6.38 (s, 1H), 5.06 (s, 2H), 3.83 (s, 3H), 
3.48−3.37 (m, 2H), 2.90−2.84 (m, 2H). 13C NMR (126 MHz, CDCl3, MeOD) δ 174.42, 
165.67, 162.04, 152.92, 152.83, 151.54, 145.18, 138.88, 136.30, 131.13, 128.14, 123.84, 
118.57, 110.07, 106.52, 56.40, 50.83, 34.70, 29.95. HRMS (ESI) m/z [M – H]− 
C19H18ClN3O4 386.0908, found 386.0903.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(pyridin-4-ylmethyl)-1H-imidazol-2-
yl)ethyl)benzoate (63)—Yield 32 mg (30%), yellow amorphous solid. 1H NMR (500 
MHz, CDCl3, MeOD) δ 8.44−8.29 (m, 2H), 6.95 (d, J = 1.4 Hz, 1H), 6.88−6.82 (m, 2H), 
6.81 (d, J = 1.5 Hz, 1H), 6.30 (s, 1H), 5.03 (s, 2H), 3.78 (s, 3H), 3.40−3.28 (m, 2H), 
2.78−2.71 (m, 2H). 13C NMR (126 MHz, CDCl3, MeOD) δ 170.39, 161.48, 157.93, 149.56 
(2C), 147.76, 146.40, 141.07, 127.39, 121.31 (2C), 120.18, 114.46, 106.24, 102.43, 52.34, 
30.70, 25.91, 25.11, 19.88. HRMS (ESI) m/z [M–H]− C19H18ClN3O4 386.0908, found 
386.0912.
Methyl 3-Chloro-4,6-dihydroxy-2-(2-(1-(pyrimidin-5-ylmethyl)-1H-imidazol-2-
yl)ethyl)benzoate (64)—Yield 45 mg (45%), white amorphous solid. 1H NMR (500 
MHz, CDCl3, MeOD) δ 9.09 (s, 1H), 8.46 (s, 2H), 7.05 (s, 1H), 6.92 (s, 1H), 6.40 (s, 1H), 
5.12 (s, 2H), 3.86 (s, 3H), 3.52−3.36 (m, 2H), 3.00−2.79 (m, 2H). 13C NMR (126 MHz, 
CDCl3, MeOD) δ 174.09, 165.38, 161.94, 159.48, 159.42, 159.38, 151.44, 144.71, 134.07, 
130.84, 123.84, 118.47, 110.37, 106.66, 56.46, 48.81, 34.66, 29.80. HRMS (ESI) m/z [M – 
H]− C18H17ClN4O4 387.0860, found 387.0861.
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5-Chlorofuran-2-carbaldehyde (65)—5-Nitrofuran-2-carbaldehyde (730 mg, 5.1 mmol) 
was stirred in conc HCl (40 mL) at 40 °C for 15 h. The reaction was poured into H2O (80 
mL) and extracted with EtOAc (3 × 50 mL). The organic layers were combined, dried 
(Na2SO4), and concentrated. The residue was purified via flash chromatography (SiO2, 1:4 
EtOAc:hexanes) to provide the title compound. Yield 266 mg (40%), yellow oil. 1H NMR 
(400 MHz, CDCl3) δ 9.53 (s, 1H), 7.23 (d, J = 3.6 Hz, 1H), 6.42 (d, J = 3.6 Hz, 1H). 13C 
NMR (126 MHz, CDCl3) δ 176.37, 152.03, 144.15, 122.67, 109.77. HRMS (ESI) m/z [M + 
H]+ for C5H4ClO2 130.9900, found 130.9900.
General Procedure for Oxime Formation
NH2OH·HCl (3 equiv) and NaOAc (3 equiv) were added to a stirred solution of aromatic 
aldehydes (1 equiv) in MeOH (0.2 M) and stirred for 8 h at rt. The reaction was quenched 
with the addition of H2O (20 mL) and EtOAc (20 mL). The organic layer was washed with 
H2O (2 × 20 mL), separated, dried (Na2SO4), and concentrated. The residue was purified via 
flash chromatography (1:10 EtOAc:hexanes to 1:3 EtOAc:hexanes) to provide the desired 
products as amorphous solids:
5-Chlorofuran-2-carbaldehyde Oxime (66a)—Yield 225 mg (75%) as a white 
amorphous solid, 1:1 mixture of isomers. 1H NMR (400 MHz, CDCl3) δ 7.91 (s, 1H), 7.46 
(s, 1H), 7.35 (d, J = 3.5 Hz, 1H), 6.61 (d, J = 3.4 Hz, 1H), 6.36 (d, J = 3.5 Hz, 1H), 6.26 (d, J 
= 3.4 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 146.42, 144.40, 139.54, 139.11, 135.93, 
121.19, 114.68, 109.78, 109.37, 108.45. HRMS (ESI) m/z [M + H]+ for C5H5ClNO2 
146.0009, found 146.0003.
Thiazole-2-carbaldehyde Oxime (66b)—Yield 510 mg (91%), white amorphous 
solid. 1H NMR (400 MHz, CDCl3) δ 8.37 (s, 1H), 7.86 (d, J = 3.2 Hz, 1H), 7.33 (dd, J = 3.3, 
0.9 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 144.69, 143.24, 142.28, 140.70, 123.45, 
119.96. HRMS (ESI) m/z [M + H]+ for C4H5N2OS 129.0123, found 129.0124.
5-Methylthiophene-2-carbaldehyde Oxime (66c)—Yield 491 mg (76%), white 
amorphous solid. 1H NMR (500 MHz, CDCl3) δ 7.62 (s, 1H), 7.21 (d, J = 3.7 Hz, 1H), 6.77 
(dd, J = 3.6, 1.1 Hz, 1H), 2.53 (d, J = 1.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 146.84, 
141.47, 132.33, 128.93, 124.83, 15.32. HRMS (ESI) m/z [M + H]+ for C6H8NOS 142.0327, 
found 142.0330.
3-Vinylthiophene-2-carbaldehyde oxime (66d)—Yield 407 mg (95%), white 
amorphous solid, 2:1 mixture of isomers. 1H NMR (400 MHz, CDCl3) δ 8.45 (s, 1H), 8.36 
(s, 2H), 7.92 (s, 2H), 7.87 (s, 1H), 7.30 (d, J = 5.3 Hz, 2H), 7.25 (d, J = 5.4 Hz, 2H), 7.20 (d, 
J = 5.3 Hz, 1H), 7.01 (d, J = 5.4 Hz, 2H), 6.84 (dd, J = 17.4, 10.9 Hz, 1H), 5.65 (d, J = 17.3 
Hz, 1H), 5.38 (d, J = 11.0 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 144.35, 143.69, 140.75, 
130.66, 130.27, 130.16, 128.09, 127.53, 127.10, 125.61, 116.88, 113.85. HRMS (ESI) m/z 
[M + H]+ for C7H8NOS 154.0327, found 154.0331.
3-Vinylfuran-2-carboxaldehyde Oxime (66e)—Yield 105 mg (48%), white amorphous 
solid. 1H NMR (400 MHz, CDCl3) δ 8.14 (s, 1H), 7.40 (d, J = 1.6 Hz, 1H), 6.76 (dd, J = 
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17.4, 10.9 Hz, 1H), 6.62 (d, J = 1.9 Hz, 1H), 5.59 (dd, J = 17.5, 1.2 Hz, 1H), 5.32 (dd, J = 
10.8, 1.2 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 144.28, 143.04, 139.55, 126.52, 125.37, 
116.55, 108.93. HRMS (ESI) m/z [M + H]+ for C7H8NO2 138.0555, found 138.0549.
5-(Bromomethyl)isoxazole (67)—N-Bromosuccinimide (2.14 g, 12 mmol, 1 equiv) and 
benzoyl peroxide (290 mg, 1.2 mmol, 0.1 equiv) were added to a stirred solution of 5-
methylisoxazole (1 g, 12 mmol) in CCl4 (50 mL). The reaction was heated to 80 °C for 5 h 
then concentrated. The resulting residue was redissolved in EtOAc (30 mL) and washed with 
H2O (3 × 20 mL). The organic layer was separated, dried (Na2SO4), and concentrated. The 
residue was purified via flash chromatography (SiO2, 1:10 EtOAc:hexanes to 3:10 
EtOAc:hexanes) to provide the title compound. Yield 725 mg (38%) as a colorless oil. 1H 
NMR (400 MHz, CDCl3) δ 8.22 (d, J = 1.6 Hz, 1H), 6.33 (d, J = 1.7 Hz, 1H), 4.49 (s, 
2H). 13C NMR (126 MHz, CDCl3) δ 166.90, 150.56, 103.07, 18.34. MS (EI) m/z [M]+ for 
C4H4BrNO 160.9, found 161.0; [M – Br]+ for C4H4NO 82.0, found 82.0.
3,5-Dimethylfuran-2-carboxylic Acid (68)—A solution of 3-methylfuran-2-carboxylic 
acid (1 g, 8 mmol, 1 equiv) in THF (3 mL) was added to a stirred solution of LDA (1 M in 
THF, 16 mmol, 2.1 equiv) at −78 °C and stirred at this temperature for 15 min followed by 
the addition of iodomethane (1 mL, 16 mmol, 2 equiv). The reaction was stirred for an 
additional 15 min at −78 °C before removal of the ice bath and slowly warming to room 
temperature. The reaction was quenched with the addition of saturated NH4Cl (50 mL). The 
organic layer was separated, and the aqueous layer was extracted with EtOAc (2 × 40 mL). 
The organic layers were combined, dried (Na2SO4), and concentrated. The residue was 
purified via flash chromatography (SiO2, 3:10 EtOAc:hexanes to 3:5 EtOAc:hexanes) to 
provide the title compound. Yield 774 mg (69%) as a white amorphous solid. 1H NMR (400 
MHz, CDCl3) δ 12.35 (br s, 1H), 6.00 (s, 1H), 2.31 (s, 3H), 2.30 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 164.38, 157.04, 138.03, 135.34, 112.39, 13.97, 11.83. HRMS (ESI) m/z [M 
+ H]+ for C7H9O3 141.0552, found 141.0551.
(3,5-Dimethylfuran-2-yl)methanol (69a)—Yield 575 mg (82%), colorless oil. 1H NMR 
(400 MHz, CDCl3) δ 5.80 (s, 1H), 4.52 (s, 2H), 2.24 (s, 3H), 1.99 (s, 3H), 1.62 (br s, 
1H). 13C NMR (126 MHz, CDCl3) δ 145.18, 124.22, 115.31, 108.96, 61.40, 13.55, 9.68. 
MS (EI) m/z [M + H]+ for C7H11O2 127.1, found 127.1.
(3-Chlorothiophen-2-yl)methanol (69b)—Yield 240 mg (36%), yellow oil. 1H NMR 
(400 MHz, CDCl3) δ 7.25 (dd, J = 5.4, 1.1 Hz, 1H), 6.90 (dd, J = 5.4, 1.1 Hz, 1H), 4.81 (dd, 
J = 6.1, 1.3 Hz, 2H), 2.04 (br s, 1H). 13C NMR (126 MHz, CDCl3) δ 135.98, 127.80, 
124.60, 123.00, 57.60. MS (EI) m/z [M]+ for C5H5ClOS 148.0, found 148.0.
(4-Chlorothiophen-2-yl)methanol (69c)—Yield 165 mg (25%), yellow oil. 1H NMR 
(400 MHz, CDCl3) δ 7.05 (s, 1H), 6.88 (s, 1H), 4.77 (d, J = 5.8 Hz, 2H), 1.92 (br s, 1H). 13C 
NMR (126 MHz, CDCl3) δ 144.73, 125.54, 124.79, 119.88, 60.09. MS (EI) m/z [M]+ for 
C5H5ClOS 148.0, found 148.0; [M + H]+ for C5H6ClOS 149.0, found 149.0.
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Assay was performed in 96-well format in black, flat bottom plates (Santa Cruz 
Biotechnology) with a final volume of 100 μL. 25 μL of assay buffer (20 mM HEPES, pH 
7.3, 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 2 mM DTT, 0.1 mg/mL BGG, and 
0.01% NP-40) containing 6 nM FITC-GDA (fluorescent tracer, stock in DMSO and diluted 
in assay buffer) and 50 μL of assay buffer containing 10 nM of either Grp94 or Hsp90α 
were added to each well. Compounds were tested in triplicate wells (1% DMSO final 
concentration). For each plate, wells containing buffer only (background), tracer in buffer 
only (low polarization control), and protein and tracer in buffer with 1% DMSO (high 
polarization control) were included. Plates were incubated at 4 °C with rocking for 24 h. 
Polarization values (in mP units) was measured at 37 °C with an excitation filter at 485 nm 
and an emission filter at 528 nm. Polarization values were correlated to % tracer bound and 
compound concentrations. The concentration at which the tracer was 50% displaced by the 
inhibitor was determined using Graphpad Prism.
X-ray Crystallography
The gene for the truncated N-terminal domain of cGrp94, NΔ41 (amino acid residues 69–
337, with residues 287–327 substituted with GGGG, as in Dollins et al.47) was synthesized 
and codon-optimized by DNA2.0 (Menlo Park, CA). The construct was designed with an N-
terminal maltose binding protein (MBP) fusion, which is cleavable by tobacco etch virus 
(TEV) protease. Fidelity of the finalized MBR-TEV-NΔ41 plasmid was confirmed by 
Eurofins MWG Operon. The plasmid for MBP-TEV-NΔ41 was transformed in Escherichia 
coli BL21(DE3). Cells were grown in Luria–Bertani broth supplemented with 100 mg/L 
ampicillin (Amresco) at 37 °C with shaking at 225 rpm. Once cells reached an OD600 = 0.6–
0.8, they were induced with 0.5 mM isopropyl-β-D-1-thiogalactopyranoside (Calbiochem) 
and were harvested by centrifugation after an additional 4 h of growth with shaking. Cells 
were solubilized in phosphate buffer (PBS, 10 mM Na2HPO4, 10 mM KH2PO4, 0.2 M 
NaCl, pH 7.2) containing protease inhibitor cocktail (Complete EDTA-free tablets, Roche), 
lysed with passage through a French Press, and the resulting lysate was clarified by ultra-
centrifugation. The MBP-TEV-NΔ41 fusion protein was purified using a 20 mL column 
packed with amylose resin (New England BioLabs) equilibrated with PBS. Protein was 
eluted with a buffer containing PBS supplemented with 1 mM EDTA and 10 mM maltose. 
MBP-TEV-NΔ41 was further fractionated with a prep grade Superdex 75 column (GE 
Healthcare) equilibrated with PBS. MBP-TEV-NΔ41 was cleaved by TEV protease 
(prepared in house using pRK793 plasmid48), and the protease was removed by passing the 
mixture over a 5 mL HisTrap HP column (GE Healthcare) equilibrated with 50 mM Tris 
buffer with 0.5 M NaCl at pH 8.0. The mixture of MBP and NΔ41 were separated by 
amylose affinity purification, followed by a Superdex 75 polishing step, as above. Any 
fractions of NΔ41 containing trace amounts of MBP were subjected to a final round of 
amylose affinity purification. The NΔ41 protein purity was assessed by SDS-PAGE 
concentrated to 30 mg/mL in a 100 mM Tris buffer at pH 7.5, as quantified by the Bradford 
assay (reagents from Amresco) using BSA as a standard. Crystals of NΔ41 were grown by 
the handing drop method by equilibration against a reservoir solution containing 35% 
PEG400, 100 mM Tris at pH 7.5, and 120 mM MgCl2. Crystals were soaked for ~30 min in 
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a solution of mother liquor containing 10 mM compound 48 (diluted from a 100 mM stock 
prepared in DMSO). After soaking, 100% glycerol was added to the drop containing the 
crystals (to a total concentration of 25%) and the crystals were cryocooled in liquid nitrogen. 
Diffraction data were collected at the Advanced Photon Source, Argonne National 
Laboratories Beamline Southeast Region Collaborateve Access Team (SER-CAT) 22-BM. 
Data were processed using XDS/XSCALE.49 The initial model was obtained by molecular 
replacement using the polypeptide chain of the Grp94-RDA structure (PDB 2GFD) the 
search model in Phaser.50 The model was iteratively built and refined suing Coot and Phenix 
refine.51 PEG 400 and glycerol ligand models were prepared by inputting the corresponding 
SMILES string, and additional restraints were generated with eLBOW in Phenix refine.50 
The model of 48 was prepared using the PRODRG2 server, with additional restraints 
generated using eLBOW.52 The structure has been deposited in the Protein Data Bank with 
the PDB accession code 5IN9.
Wound-Healing Scratch Assay
MDA-MB-231 cells (ATCC) were grown to confluence and seeded at 200,000 cells/well/mL 
in a 12-well plate and grown to confluence. Each well was scratched twice with a 20–200 μL 
pipet tip. Compounds were then added (0.25% DMSO final concentration) and 0 h pictures 
were taken with an Olympus IX-71 microscope (10× objective) and the plates were returned 
to the incubator until 24 h pictures were taken. Images were processed and % wound closure 
was determined using ImageJ. All experiments were performed in quadruplicate.
Anti-Proliferative Assay
MDA-MB-231 cells were grown to confluence and seeded at 2000 cells/well/0.1 mL in a 96-
well plate and placed back in the incubator for 24 h. Compounds or vehicle were 
administered at the desired concentrations (1% DMSO final concentration) and incubated 
for 72 h. The % viable cells was determined using the MTS/PMS cell proliferation kit 
(Promega) per the manufacturer’s instructions. Cells treated with vehicle were normalized to 
100% proliferation and values adjusted accordingly.
Western Blot Analysis
MDA-MB-231 cells were grown to confluence and seeded at 200,000 cells/mL in a 10 cm 
dish and placed back in the incubator for 24 h. Compounds or vehicle were administered at 
the desired concentrations (0.25% DMSO final concentration) and incubated for 24 h. Cells 
were then harvested in cold PBS and lysed using MPER (Thermo Scientific) supplemented 
with protease inhibitors (Roche) according to the manufacturer’s instructions. Cell lysates 
were obtained by centrifugation at 14000g for 15 min at 4 °C. Protein concentrations for 
each sample were determined using the Pierce BCA assay kit following the manufacturer’s 
directions. Equal amounts of proteins (20 μg) were separated using gel electrophoresis under 
reducing conditions (10% acrylamide gels) then transferred to PVDF membranes and 
immunoblotted with the corresponding primary antibodies. Membranes were then incubated 
with the correct HRP-labeled secondary antibody, developed with a chemiluminescent 
substrate, and visualized.
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ABBREVIATIONS
Grp94 glucose-regulated protein 94
Hsp90 and Hsp70 heat shock protein 90 and 70
ER endoplasmic reticulum
TLR toll-like receptor




POAG primary open angle glaucoma
ERAD endoplasmic reticulum associated degradation
TM trabecular meshwork
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Purine-based Grp94-selective inhibitors (1, 2, and 3). Resorcinol-based pan-Hsp90 (4) and 
Grp94-selective (5) inhibitors.
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Co-crystal structures of RDA with Hsp90 isoforms. cGrp94 (A, PDB 2GFD) highlights the 
hydrophobic and π-rich nature of the unique secondary binding pocket of Grp94. Only cis-
RDA shown for clarity. yHsp82 (B, PDB 2FXS) highlights the hydrogen bonding network 
present and restricted access to the aromatic residues. Residues are numbered as in their 
respective proteins. BnIm docked in to Gpr94 (C) highlighting substitution positions on the 
aryl side chain.
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(A) Tertiary structure of RDA bound to Grp94 (PDB 2GFD) showing the open conformation 
of the N-terminal domain of Grp94. (B) Tertiary structure of 3 bound to Grp94 (PDB 3O2F) 
showing the conformational shift (blue, green, and orange helices) of the N-terminal domain 
induced by the inhibitor binding to Grp94 revealing the extended binding pocket.
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Overlay of the minimized structures of BnIm (cyan) and 46 (green) highlighting the 
overlapping 4- and 5-positions, respectively.
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Crystal structure of 48 bound to Grp94. (a) Surface representation of ATP-binding pocket 
with 48 as ball and stick. Arrow points to a well-ordered loop at the mouth of the active site. 
(b) Cartoon representation of the structure as in (a) highlighting H-bonding interactions 
(≤3.5 Å) and loop configuration. (c) Zoomed view of 48 in active site with H-bonding 
interactions as in (b). (d) Final 2Fo – Fc electron density contoured at 1 σ (gray mesh) 
superimposed with initial Fo – Fc density contoured at 3 σ (green) after molecular 
replacement (see Experimental Section).
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Wound-healing scratch assay results after 24 h treatment with BnIm, 40, 48, or vehicle. 
Antiproliferative activity given is relative to vehicle control (n = 4). ND = not determined.
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(A) Western blot analysis of MDA-MB-231 cells treated with Grp94-selective inhibitors, 
geldanamycin (GDA, a pan-Hsp90 inhibitor), or vehicle control (DMSO, 0.25% final 
concentration). Ratio of Integrin α2 (B), Akt (C), and Hsp70 (D) normalized to actin for 
each compound concentration.
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Western blot analysis of HEK cells overexpressing the I477N myocilin mutant and treated 
with 1 μM of indicated Grp94-selective inhibitors illustrating (A) myocilin degradation and 
(B) lack of AKT degradation and Hsp70 induction. Ratio of myocilin (C), AKT (D), and 
Hsp70 (E) normalized to actin for each compound. Vehicle = DMSO and 17-AAG = 17-
(allylamino)-17-demethoxygeldanamycin (pan-Hsp90 N-terminal inhibitor).
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Summary of structure–activity relationships for the BnIm series of Grp94-selective 
inhibitors.
Crowley et al. Page 41














aConditions: (a) LiAlH4, THF, 0–25 °C, 12 h; (b) DBU, DPPA, toluene, 0–25 °C, 12 h; (c) 
PPh3, THF:H2O (10:1), 25 °C, 12 h.
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Scheme 3. Synthesis of Amines from Aromatic Aldehydesa
aConditions: (a) HNO3, H2SO4, Ac2O, 0 °C, 1 h; (b) 50% H2SO4 (aq), 110 °C, 5 min; (c) 
conc HCl, 40 °C, 12 h; (d) NH2OH·HCl, NaOAc, MeOH, 25 °C, 8 h; (e) LiAlH4, THF, 0–
25 °C, 12 h; (f) potassium vinyltrifluoroborate, Pd(dppf)Cl2, iPr2EtN, toluene, 110 °C, 14 h; 
(g) H2, 10% Pd/C, EtOH, 25 °C, 6 h.
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aConditions: (a) SO2Cl2, 15 °C, AcOH:Et2O (9:1), 1 h; (b) NBS, AIBN, CCl4, 80 °C, 4 h; 
(c) NaN3, MeOH:H2O (10:1), 25 °C, 12 h; (d) PPh3, THF:H2O (10:1), 25 °C, 12 h; (e) 
LiOH, THF:MeOH:-H2O (9:1:1), 25 °C, 10 h; (f) LDA, MeI, THF, −40 °C, 3 h; (g) LiAlH4, 
THF, 0–25 °C, 12 h; (h) DBU, DPPA, toluene, 25 °C, 12 h; (i) n-BuLi, CO2(g), THF, 
−78 °C, 2 h.
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